Document:

exv10w53

Exhibit 10.53

ALEXZA PHARMACEUTICALS, INC.

SECURITIES PURCHASE AGREEMENT

     This Securities Purchase Agreement (this “Agreement”) is made as of September 29,
2009, by and among Alexza Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
with its principal office at 2091 Stierlin Court, Mountain View, California 94043, and the
individuals and entities identified on the signature pages hereto (the “Purchasers”).

RECITALS

     Whereas, the Company has authorized the sale and issuance of the Common Shares and
the Warrants (each as defined herein);

     Whereas, the Company and the Purchasers are executing and delivering this Agreement
in reliance upon the exemption from securities registration afforded by the provisions of Section
4(2) of the Securities Act (as defined herein) and Regulation D, as promulgated by the SEC (as
defined herein) under the Securities Act; and

     Whereas, at the Closing (as defined herein), the Company desires to sell, and each
Purchaser desires severally, and not jointly, to purchase, the Common Shares and the Warrants, each
as indicated below such Purchaser’s name on the applicable signature page hereto, upon the terms
and conditions stated in this Agreement.

     Now, Therefore, in consideration of the foregoing recitals and the mutual promises,
representations, warranties and covenants hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

ARTICLE 1

Authorization and Sale of Common Shares and Warrants

     1.1 Authorization. The Company has authorized (a) the sale and issuance of up to 8,107,013
shares (the “Common Shares”) of the Company’s common stock, par value $0.0001 per share (the
“Common Stock”), and (b) the sale and issuance of warrants, in the form attached hereto as Exhibit
A (the “Warrants”), to purchase up to 7,296,312 shares of the Common Stock at an exercise price of
$2.77 per share, pursuant to this Agreement. The shares of Common Stock issuable upon exercise of
or otherwise pursuant to the Warrants are referred to herein as the “Warrant Shares.” The Common
Shares and the Warrant Shares are collectively referred to herein as the “Shares.” The Shares and
the Warrants are collectively referred to herein as the “Securities.”

     1.2 Sale of Common Shares and Warrants. At the Closing, subject to the terms and conditions
of this Agreement, including without limitation, the conditions set forth in Article 5 and Article
6 of this Agreement, the Company shall issue and sell to each Purchaser and each Purchaser shall
severally, and not jointly, purchase from the Company Common Shares in the

 1.

 

amount indicated below such Purchaser’s name on the applicable signature page hereto and
Warrants to purchase shares of the Common Stock in the amount indicated below such Purchaser’s name
on the applicable signature page hereto, in exchange for the cash consideration set forth as the
“Purchase Price” indicated below such Purchaser’s name on the applicable signature page hereto.
The portion of the “Purchase Price” attributable to the Common Shares is $2.32 per share and the
portion of the “Purchase Price” attributable to each Warrant to purchase Common Stock is $0.125 per
whole share of such Common Stock.

ARTICLE 2

Closing Dates; Delivery

     2.1 Closing Date. Subject to the satisfaction (or waiver) of the conditions thereto set forth
in Article 5 and Article 6 of this Agreement, the closing of the purchase and sale of the Common
Shares and Warrants hereunder (the “Closing”) shall be held at the offices of Cooley Godward
Kronish llp (“Cooley”), 380 Interlocken Crescent, Suite 900, Broomfield, Colorado 80021,
at 10:00 a.m. local time on October 5, 2009, or at such other time and place upon which the Company
and the Purchasers purchasing a majority of the Common Shares at the Closing shall agree. The date
of the Closing is hereinafter referred to as the “Closing Date.”

     2.2 Delivery. At the Closing, the Company will deliver or cause to be delivered to each
Purchaser a duly executed Warrant and a certificate representing the number of Common Shares
purchased by such Purchaser. Such delivery shall be against payment of the purchase price therefor
by each such Purchaser as set forth as the “Purchase Price” indicated below such Purchaser’s name
on the applicable signature page hereto by wire transfer of immediately available funds to the
Company in accordance with the Company’s written wiring instructions.

ARTICLE 3

Representations and Warranties of the Company

     The Company represents and warrants to the Purchasers on and as of the date hereof:

     3.1 Organization and Standing. The Company is a corporation duly organized and validly
existing under, and by virtue of, the laws of the State of Delaware and is in good standing as a
domestic corporation under the laws of said state. The Company is duly qualified as a foreign
corporation to transact business and is in good standing in each other jurisdiction in which such
qualification is required, except where the failure to so qualify or be in good standing would not,
either individually or in the aggregate, reasonably be expected to have a material adverse effect
on the Company’s properties or assets or the business of the Company as currently conducted (a
“Material Adverse Effect”).

     3.2 Subsidiaries. Except as disclosed in the SEC Documents (as defined herein), the Company
does not own or control any equity security or other interest of any corporation, limited
partnership or other business entity. All of the direct and indirect subsidiaries of the Company
are set forth in the SEC Documents (the “Subsidiaries”). The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of

 2.

 

any liens, and all the issued and outstanding shares of capital stock of each Subsidiary are
validly issued and are fully paid, non-assessable and free of preemptive and similar rights. Each
Subsidiary is an entity duly incorporated or otherwise organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or organization (as applicable),
with the requisite power and authority to own and use its properties and assets and to carry on its
business as currently conducted. The representations made in this Section 3 shall be deemed to
include and be made on behalf of the Subsidiaries where appropriate.

     3.3 Corporate Power; Authorization. The Company has all requisite legal and corporate power
and has taken all requisite corporate action to execute and deliver this Agreement and the
Warrants, to sell and issue the Common Shares and Warrants, to issue the Warrant Shares upon
exercise of the Warrants in accordance with the terms of such Warrants, and to carry out and
perform all of its obligations under this Agreement and the Warrants. This Agreement constitutes,
and upon execution and delivery by the Company of the Warrants, the Warrants will constitute,
legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms, except (a) as limited by applicable bankruptcy, insolvency,
reorganization or similar laws relating to or affecting the enforcement of creditors’ rights
generally and (b) as limited by equitable principles generally. The execution and delivery of this
Agreement does not, the performance of this Agreement and the compliance with the provisions hereof
will not, and the issuance, sale and delivery of the Common Shares and the Warrants by the Company
will not, materially conflict with, or result in a material breach or violation of the terms,
conditions or provisions of, or constitute a material default under, or result in the creation or
imposition of any material lien pursuant to the terms of, the Company’s Restated Certificate of
Incorporation (the “Restated Certificate”), or the Company’s Amended and Restated Bylaws, as
amended (the “Bylaws”), or any statute, law, rule or regulation or any state or federal order,
judgment or decree or any indenture, mortgage, lease or other material agreement or instrument to
which the Company or any of its properties is subject. Except as disclosed in the SEC Documents,
there are no stockholder agreements, voting agreements, or other similar arrangements with respect
to the Company’s capital stock to which the Company is a party or, to the Company’s knowledge,
between or among any of the Company’s stockholders.

     3.4 Issuance and Delivery of the Shares. The Shares have been duly authorized, and when
issued in compliance with the provisions of this Agreement and the Restated Certificate, the Common
Shares will be validly issued, fully paid and nonassessable. Upon exercise of the Warrants in
accordance with the terms thereof, the Warrant Shares will be validly issued, fully paid and
nonassessable. The issuance and delivery of the Common Shares, the Warrants, and Warrant Shares is
not subject to preemptive or any other similar rights of the stockholders of the Company or to any
liens or encumbrances. Assuming the accuracy of the representations and warranties of the
Purchasers in this Agreement, the Shares, Warrants and Warrant Shares will be issued in compliance
with all applicable federal and state securities laws.

     3.5 SEC Documents; Financial Statements. The Company has filed in a timely manner all
documents that the Company was required to file with the Securities and Exchange Commission (the
“SEC”) under Sections 13, 14(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), during the 12 months preceding the date of this Agreement, except for the late
filing of a Current Report on Form 8-K, which filing was made on

 3.

 

March 27, 2009. As of their respective filing dates, all documents filed by the Company with
the SEC (the “SEC Documents”) complied in all material respects with the requirements of the
Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), as applicable. None
of the SEC Documents as of their respective dates contained any untrue statement of material fact
or omitted to state a material fact required to be stated therein or necessary to make the
statements made therein, in light of the circumstances under which they were made, not misleading.
The financial statements of the Company included in the SEC Documents (the “Financial Statements”)
comply as to form in all material respects with applicable accounting requirements and with the
published rules and regulations of the SEC with respect thereto. The Financial Statements have
been prepared in accordance with generally accepted accounting principles consistently applied and
fairly present the consolidated financial position of the Company and any subsidiaries at the dates
thereof and the consolidated results of their operations and consolidated cash flows for the
periods then ended (subject, in the case of unaudited statements, to normal, recurring adjustments
or to the extent that such unaudited statements do not include footnotes). Except as disclosed in
the SEC Documents, since December 31, 2008, the Company has not altered materially its method of
accounting or the manner in which it keeps its accounting books and records. Except as disclosed
in the SEC Documents, the Company has not declared or made any dividend or distribution of cash or
other property to its stockholders or purchased, redeemed or made any agreements to purchase or
redeem any shares of its capital stock (other than in connection with repurchases of unvested stock
issued to employees of the Company). The Company has not issued any equity securities to any
officer, director or affiliate, except (a) Common Stock issued pursuant to existing Company stock
option or stock purchase plans or executive and director corporate arrangements disclosed in the
SEC Documents, (b) Common Stock issued pursuant to other existing agreements disclosed in the SEC
Documents or (c) otherwise as disclosed in the SEC Documents. The Company has no liabilities or
obligations required to be disclosed in the SEC Documents that are not so disclosed in the SEC
Documents, which, individually or in the aggregate, would have or reasonably be expected to have a
Material Adverse Effect.

     3.6 Material Contracts. All material agreements that were required to be filed as exhibits to
the SEC Documents under Item 601 of Regulation S-K (collectively, the “Material Agreements”) to
which the Company is a party, or the property or assets of the Company are subject, have been filed
as exhibits to the SEC Documents. All Material Agreements are valid and enforceable against the
Company in accordance with their respective terms, except (a) as limited by applicable bankruptcy,
insolvency, reorganization or similar laws relating to or affecting the enforcement of creditors’
rights generally and (b) as limited by equitable principles generally. The Company is not in
breach of or default under any of the Material Agreements, and to the Company’s knowledge, no other
party to a Material Agreement is in breach of or default under such Material Agreement, except in
each case, for such breaches or defaults as would not reasonably be expected to have a Material
Adverse Effect. The Company has not received a notice of termination nor is the Company otherwise
aware of any threats to terminate any of the Material Agreements.

     3.7 Compliance in Clinical Trials. The clinical trials conducted by or on behalf of the
Company that are described in the SEC Documents, investor presentations, exhibits, documents
incorporated by reference and annexes thereto (the “Transaction Documents”) or the results of which
are referred to in the documents relating to this Agreement and the purchase of

 4.

 

the Common Shares and Warrants, if any, are the only clinical trials currently being conducted
by or on behalf of the Company. Nothing has come to the attention of the Company that has caused
the Company to believe that such studies and tests were and, if still pending, are being, conducted
not in accordance with experimental protocols, procedures and controls pursuant to accepted
professional scientific standards and applicable local, state and federal laws, rules, regulations
and guidances, including, but not limited to, the principles of Good Clinical Practice, the Federal
Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312,
and has made all reports, filings and notifications required thereunder, including, but not limited
to, the reports required by 21 C.F.R. § 312.32; the descriptions of the results of such studies,
tests and trials contained in the Transaction Documents, if any, are not inconsistent with such
results in any material respects. Except as described in the Transaction Documents, no results of
any other studies or tests have come to the attention of the Company that have caused the Company
to believe that such results call into question the results described in the Transaction Documents
of the clinical trials. The Company has not received any notices or correspondence from the FDA or
any other governmental agency requiring the termination, suspension or modification of any clinical
trials currently conducted by, or on behalf of, the Company or in which the Company has
participated that are described in the Transaction Documents, if any, or the results of which are
referred to in the Transaction Documents. Nothing has come to the attention of the Company that
has caused the Company to believe that the clinical trials previously conducted by or on behalf of
the Company while conducted by or on behalf of the Company, were not conducted in accordance with
experimental protocols, procedures and controls pursuant to accepted professional scientific
standards; the descriptions of the results of such studies, tests and trials contained in the
Transaction Documents, if any, are not inconsistent with such results.

     3.8 Governmental Consents. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state, or local governmental
authority on the part of the Company is required in connection with the consummation of the
transactions contemplated by this Agreement except for (a) compliance with the securities and blue
sky laws in the states in which the Common Shares and Warrants are offered and/or sold, which
compliance will be effected in accordance with such laws, (b) the filing of the Registration
Statement (as defined herein) and any amendments thereto with the SEC as contemplated by
Section 7.2 of this Agreement, (c) the filing of the NASDAQ Stock Market Notification Form with The
NASDAQ Stock Market (“NASDAQ”) and (d) the filing of a Form D with the SEC.

     3.9 No Material Adverse Change. Except as otherwise disclosed herein or in the SEC Documents,
since June 30, 2009, there have not been any changes in the authorized capital, assets,
liabilities, financial condition, business, Material Agreements or operations of the Company from
that reflected in the Financial Statements except changes in the ordinary course of business which
have not been, either individually or in the aggregate, materially adverse.

     3.10 Authorized Capital Stock. The authorized capital stock of the Company consists of
(a) 100,000,000 shares of Common Stock, $0.0001 par value, of which, as of September 25, 2009,
43,279,370 shares were outstanding, and (b) 5,000,000 shares of Preferred Stock, $0.0001 par value,
none of which shares are currently outstanding. Except as disclosed in the SEC Documents and as
contemplated by this Agreement, there are no outstanding warrants,

 5.

 

debt securities, notes, credit agreements, credit facilities or other agreements, documents or
instruments evidencing indebtedness of the Company or by which the Company is bound, options,
convertible securities or other rights, agreements or arrangements of any character under which the
Company is or may be obligated to issue any equity securities of any kind. No shares of the
Company’s outstanding capital stock are subject to preemptive rights or any other similar rights.
Except as disclosed in the SEC Documents or set forth in this Agreement, there are no agreements or
arrangements under which the Company is obligated to register the sale of any of their securities
under the Securities Act.  There are no outstanding securities or instruments of the Company which
contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company is or may become bound to redeem a security of
the Company. There are no securities or instruments containing anti-dilution or similar provisions
that will be triggered by the issuance of the Shares. Except as disclosed in the SEC Documents,
the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or
any similar plan or agreement.

     3.11 Litigation. There are no actions, suits, proceedings or investigations pending or, to
the Company’s knowledge, threatened against the Company or any of its properties or, to the
Company’s knowledge, any of its directors or officers before or by any court or arbitrator or any
governmental body, agency or official in which there is a reasonable likelihood (in the judgment of
the Company) of an adverse decision that (a) could have a material adverse effect on the Company’s
properties or assets or the business of the Company as currently conducted or (b) could impair the
ability of the Company to perform in any material respect its obligations under this Agreement or
affects or challenges the legality, validity or enforceability of this Agreement or the Shares.
Neither the Company, nor, to the Company’s knowledge, any director or officer thereof, is or has
been the subject of any action involving a claim of violation of or liability under federal or
state securities laws relating to the Company. There has not been, and to the Company’s knowledge,
there is not pending or contemplated, any investigation by the SEC involving the Company or, to the
Company’s knowledge, any current or former director or officer of the Company. The Company has not
received any stop order or other order suspending the effectiveness of any registration statement
filed by the Company under the Securities Act and, to the Company’s knowledge, the SEC has not
issued any such order. There are no material disagreements presently existing, or reasonably
anticipated by the Company to arise, between the accountants formerly or presently employed by the
Company.

     3.12 Company not an “Investment Company.” The Company is not, and immediately after receipt
of payment for the Shares will not be, an “investment company” or an affiliate thereof or an entity
“controlled” by an “investment company” within the meaning of the Investment Company Act of 1940,
as amended (the “Investment Company Act”), and shall conduct its business in a manner so that it
will not become subject to the Investment Company Act.

     3.13 NASDAQ Compliance. The Common Stock is registered pursuant to Section 12(b) of the
Exchange Act and is listed on NASDAQ, and the Company has taken no action designed to, or likely to
have the effect of, terminating the registration of the Common Stock under the Exchange Act or
de-listing the Common Stock from NASDAQ, nor has the Company received any notification that the
SEC, the Financial Industry Regulatory Authority or NASDAQ is contemplating terminating such
registration or listing. The Company is in

 6.

 

compliance with all applicable listing and maintenance requirements of NASDAQ. The issuance
and sale of the Shares and the Warrants under this Agreement does not contravene the rules and
regulations of NASDAQ, and no approval of the stockholders of the Company thereunder is required
for the Company to issue and deliver the Common Shares and the Warrants to the Purchasers.

     3.14 OFAC. Neither the Company nor, to the Company’s knowledge, any director, officer, agent,
employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), and the Company will not
intentionally directly or indirectly use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or
entity, for the purpose of financing the activities of any person currently subject to any U.S.
sanctions administered by OFAC.

     3.15 Use of Proceeds. The proceeds of the sale of the Common Shares and the Warrants
hereunder shall be used by the Company for working capital and general corporate purposes.

     3.16 No Directed Selling Efforts or General Solicitation. Neither the Company nor any person
or entity acting on its behalf has conducted any general solicitation or general advertising (as
those terms are used in Regulation D under the Securities Act) in connection with the offer or sale
of any of the Securities.

     3.17 Brokers and Finders. Other than RBC Capital Markets Corporation (“RBC”), no person or
entity will have, as a result of the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Company or a Purchaser for any commission, fee or other
compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf
of the Company with respect to the offer and sale of the Securities. The Company shall indemnify,
pay, and hold each Purchaser harmless against, any liability, loss or expense (including, without
limitation, attorneys’ fees and out-of-pocket expenses) arising in connection with any such right,
interest or claim.

     3.18 No Integrated Offering. Neither the Company nor any of its affiliates, nor any person or
entity acting on its or their behalf has, directly or indirectly, made any offers or sales of any
Company security or solicited any offers to buy any security, under circumstances that would
adversely affect reliance by the Company on Section 4(2) of the Securities Act for the exemption
from registration for the transactions contemplated hereby or would require registration of the
Securities under the Securities Act.

     3.19 Private Placement. Assuming the accuracy of the representations and warranties of the
Purchasers contained in Sections 4.2 and 4.3 hereof, the offer and sale of the Securities to the
Purchasers as contemplated hereby is exempt from the registration requirements of the Securities
Act.

     3.20 No Manipulation of Stock. Neither the Company nor, to its knowledge, any of its
affiliates has taken, directly or indirectly, any action designed to or which has constituted or
which might reasonably be expected to cause or result, under the Exchange Act or otherwise, in

 7.

 

the stabilization or manipulation of the price of any securities of the Company facilitate the
sale or resale of the Common Shares and the Warrants.

     3.21 Intellectual Property.

          (a) “Intellectual Property” shall mean patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information and other proprietary rights and processes.

          (b) Except as disclosed in the SEC Documents, the Company owns or has the valid right to use
all of the Intellectual Property that is necessary for the conduct of the Company’s business as
currently conducted or as currently proposed to be conducted as described in the SEC Documents,
free and clear of all material liens and encumbrances.

          (c) Except as disclosed in the SEC Documents, the conduct of the Company’s business as
currently conducted does not infringe or otherwise conflict with (collectively, “Infringe”) any
Intellectual Property rights of any third party or any confidentiality obligation owed by the
Company to a third party, and, to the knowledge of the Company, the Intellectual Property and
confidential information of the Company are not being Infringed by any third party. There is no
pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others
challenging the Company’s rights in or to any such Intellectual Property. There is no pending or,
to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the
validity or scope of any such Intellectual Property. There is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or
otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of
others.

          (d) Each employee, consultant and contractor of the Company who has had access to confidential
information of the Company that is necessary for the conduct of Company’s business as currently
conducted or as currently proposed to be conducted has executed an agreement to maintain the
confidentiality of such confidential information that is substantially consistent with the
Company’s standard forms thereof.

     3.22 Compliance with Laws. The Company (a) is in compliance in all material respects with all
applicable laws, rules, regulations, orders, decrees and judgments applicable to it, including,
without limitation any and all applicable foreign, federal, state and local laws and regulations
relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (“Applicable Laws”), (b) has received all material
permits, licenses or other approvals required under Applicable Laws to conduct its business and
(c) is in compliance in all material respects with all terms and conditions of any such permit,
license or approval. There are no material costs or liabilities associated with Applicable Laws,
including, without limitation, any capital or operating expenditures required for clean-up, closure
of properties or compliance with Applicable Laws or any permit, license or approval, any related
constraints on operating activities and any potential liabilities to third parties. The Company has
not received any notice of purported or actual non-compliance with Applicable Laws nor, except to
the extent it would not individually or in the aggregate reasonably be expected to have a Material
Adverse Effect, any notice of any material, actual or

 8.

 

proposed changes in the existing Applicable Laws. The Company has not received any
communication from any governmental authority (i) threatening to revoke any permit, license,
franchise, certificate of authority or other governmental authorization, or (ii) threatening or
contemplating revocation or limitation of, or which would have the effect of prohibiting or
limiting the Company’s business as is currently conducted in any material respect. The Company is
not subject to any claim relating to any Applicable Laws which claim has had or would reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect, and, to the
Company’s knowledge, there is no pending or threatened investigation that might lead to such a
claim. The Company possesses or has applied for all certificates, authorizations and permits
issued by the appropriate federal, state, local or foreign regulatory authorities necessary to
conduct their respective businesses as currently conducted and as described in the SEC Documents,
except where the failure to possess such permits, individually or in the aggregate, has not and
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect (“Material Permits”), and (i) the Company has not received any notice in writing of
proceedings relating to the revocation or material adverse modification of any such Material
Permits and (ii) the Company is unaware of any facts or circumstances that would give rise to the
revocation or material adverse modification of any Material Permits.

     3.23 Title. The Company has good and marketable title to all personal property owned by it
that is material to the business of the Company, free and clear of all liens, encumbrances and
defects except as described in the SEC Documents or such as do not materially affect the value of
such property and do not interfere with the use made and proposed to be made of such property by
the Company. Any real property and buildings held under lease by the Company is held under valid,
subsisting and enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the Company. The
Company does not own any real property.

     3.24 Employment Matters. No material labor dispute with the employees of the Company exists
or, to the knowledge of the Company, is imminent. No collective bargaining agreement exists with
any of the Company’s employees and, to the Company’s knowledge, no such agreement is imminent. The
Company is in compliance with all U.S. federal, state, local and foreign laws and regulations
relating to employment and employment practices, terms and conditions of employment and wages and
hours, except where the failure to be in compliance would not have or reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

     3.25 Questionable Payments. Neither the Company nor, to the knowledge of the Company, any of
its current or former stockholders, directors, officers, employees, agents or other persons acting
on behalf of the Company, has on behalf of the Company or in connection with its business: (a) used
any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses
relating to political activity; (b) made any direct or indirect unlawful payments to any
governmental officials or employees from corporate funds; (c) established or maintained any
unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious
entries on the books and records of the Company; (e) made any unlawful bribe, rebate, payoff,
influence payment, kickback or other unlawful payment of any
nature or (f) 

 9.

 

violated or is in violation of in any material respect any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended.

     3.26 Transactions with Affiliates. Except as disclosed in the SEC Documents and as
contemplated pursuant to this Agreement, none of the officers or directors of the Company and, to
the knowledge of the Company, none of the employees of the Company is presently a party to any
transaction with the Company or to a presently contemplated transaction (other than for services as
employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of
Regulation S-K promulgated under the Securities Act. There is no transaction, arrangement, or
other relationship between the Company and an unconsolidated or other off balance sheet entity that
is required to be disclosed by the Company in the SEC Documents and is not so disclosed and would
have or reasonably be expected to have a Material Adverse Effect.

     3.27 Disclosure. The information contained in the Exchange Act Documents as of the date
hereof does not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. For purposes herein, “Exchange Act
Documents” are the documents filed by the Company under the Exchange Act, since the end of the
Company’s 2008 fiscal year through the date hereof, including, without limitation, its most recent
annual report on Form 10-K. The Company confirms that neither it nor any of its officers or
directors nor any other Person acting on its or their behalf has provided, and it has not
authorized any other party to provide, any Purchaser or its respective agents or counsel with any
information that it believes constitutes or could reasonably be expected to constitute material,
non-public information except insofar as the existence, provisions and terms of this Agreement and
the proposed transactions hereunder may constitute such information, all of which will be disclosed
by the Company in the press release(s) as contemplated by Section 7.8 hereof. The Company
understands and confirms that each of the Purchasers will rely on the foregoing representations in
effecting transactions in securities of the Company. No event or circumstance has occurred or
information exists with respect to the Company or its business, properties, operations or financial
conditions, which, under applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly announced or disclosed, except for
the announcement of this Agreement and related transactions and as may be disclosed in the Current
Report on Form 8-K filed by the Company.

     3.28 Sarbanes-Oxley; Disclosure Controls and Procedures. The Company is in compliance in all
material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 that are applicable
to it. Except as disclosed in the SEC Documents, the Company has established and maintains
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that
are effective in all material respects to ensure that material information relating to the Company
is made known to its chief executive officer and chief financial officer by others within the
Company. The Company’s certifying officers have evaluated the effectiveness of the Company’s
disclosure controls and procedures as of the end of the period covered by its most recently filed
quarterly or annual periodic report under the Exchange Act (such date, the “Evaluation Date”). The
Company presented in its most recently filed quarterly or annual periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the Company’s disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there has been no change

 10.

 

in the Company’s internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting.

     3.29 Taxes. The Company has filed (or has obtained an extension of time within which to file)
all necessary federal, state and foreign income and franchise tax returns and has paid all taxes
shown as due on such tax returns. The Company is not aware of any tax deficiency that has been or
might be asserted or threatened against it that would reasonable be expected to have a Material
Adverse Effect.

     3.30 Insurance. The Company is insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as the Company believes are prudent and customary
for a company (i) in the business in which the Company is engaged, (ii) with the resources of the
Company and (iii) at a similar stage of development as the Company. The Company has not received
any written notice of cancellation of such insurance or that the Company will not be able to renew
its existing insurance coverage as and when such coverage expires. The Company believes it will be
able to obtain similar coverage at reasonable cost from similar insurers as may be necessary to
continue its business.

     3.31 Shell Company Status. The Company is not a shell company, and is not, and has never been,
an issuer identified in Rule 144(i)(1).

     3.32 Application of Takeover Protections; Rights Agreements. Except as disclosed in the SEC
Documents, the Company has not adopted any stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Common Stock or a change in control of the Company.
The Company and its board of directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the Company’s
certificate of incorporation or other organizational documents or the laws of the jurisdiction of
its incorporation or otherwise which is or could become applicable to any Purchaser solely as a
result of the transactions contemplated by this Agreement, including, without limitation, the
Company’s issuance of the Shares and any Purchaser’s ownership of the Shares.

     3.33 No Additional Agreements. The Company does not have any agreement or understanding with
any Purchaser with respect to the transactions contemplated by this Agreement other than as
specified in this Agreement.

ARTICLE 4

Representations, Warranties and Covenants of the Purchasers

     Each Purchaser hereby severally, and not jointly, represents and warrants to and agrees with
the Company on and as of the date hereof:

     4.1 Authorization. Purchaser represents and warrants to the Company that: (a) Purchaser has
all requisite legal and corporate or other power and capacity and has taken all requisite corporate
or other action to execute and deliver this Agreement, to purchase the

 11.

 

Common Shares and the Warrants to be purchased by it and to carry out and perform all of its
obligations under this Agreement; and (b) this Agreement constitutes the legal, valid and binding
obligation of such Purchaser, enforceable against such Purchaser in accordance with its terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating
to or affecting the enforcement of creditors’ rights generally and (ii) as limited by equitable
principles generally.

     4.2 Investment Experience. Purchaser is an “accredited investor” as defined in Rule 501(a)
under the Securities Act. Purchaser is aware of the Company’s business affairs and financial
condition and has had access to and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision to acquire the Common Shares and the Warrants. Purchaser
has such business and financial experience as is required to give it the capacity to protect its
own interests in connection with the purchase of the Common Shares and Warrants.

     4.3 Investment Intent. Purchaser is purchasing the Common Shares and the Warrants for its own
account as principal and not with a present view to, or for, resale, distribution or
fractionalization thereof, in whole or in part, within the meaning of the Securities Act. Purchaser
understands that its acquisition of the Common Shares and the Warrants has not been registered
under the Securities Act or registered or qualified under any state securities law in reliance on
specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide
nature of Purchaser’s investment intent as expressed herein. Purchaser, in connection with its
decision to purchase the Common Shares and the Warrants, has relied solely upon the SEC Documents
and the representations and warranties of the Company contained herein. Purchaser will not,
directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any
offers to buy, purchase or otherwise acquire or take a pledge of) any of the Securities except in
compliance with the Securities Act and the rules and regulations promulgated thereunder.

     4.4 Registration or Exemption Requirements. Purchaser further acknowledges and understands
that the Securities may not be resold or otherwise transferred except pursuant to an effective
registration statement or unless an exemption from such registration is available.

     4.5 Dispositions.

          (a) Purchaser will not, prior to the effectiveness of the Registration Statement, if then
prohibited by law or regulation: (i) sell, offer to sell, solicit offers to buy, dispose of, loan,
pledge or grant any right with respect to (collectively, a “Disposition”) the Securities; or (ii)
engage in any hedging or other transaction (including, without limitation, any Short Sales
involving the Company’s securities) which is designed or could reasonably be expected to lead to or
result in a Disposition of Securities by such Purchaser or an affiliate. In addition, Purchaser
agrees that for so long as it owns any Shares, it will not enter into any Short Sale of the Common
Stock executed at a time when Purchaser has no equivalent offsetting long position in the Common
Stock. For purposes of determining whether Purchaser has an equivalent offsetting long position in
the Common Stock, shares of Common Stock that Purchaser is entitled to receive within 60 days
(whether pursuant to contract or upon conversion or exercise of convertible securities) will be
included as if held long by Purchaser.

 12.

 

          (b) Purchaser has not directly or indirectly, nor has any Person acting on behalf of or
pursuant to any understanding with such Purchaser, engaged in any transactions in the Company’s
securities (including, without limitation, any Short Sales involving the Company’s securities)
since the time that such Purchaser was first contacted by the Company or any other Person regarding
the transactions contemplated hereby. Such Purchaser covenants that neither it nor any Person
acting on its behalf or pursuant to any understanding with it will engage in any transactions in
the Company’s securities (including, without limitation, any Short Sales involving the Company’s
securities) prior to the time that the transactions contemplated by this Agreement are publicly
disclosed.

     For purposes of this Section 4.5, (i) “Person” shall include, without limitation, any
individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company or joint stock company and (ii) “Short Sales” shall include,
without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under
the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps and similar arrangements (including on a total return
basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated
brokers.

     4.6 No Legal, Tax or Investment Advice. Purchaser understands that nothing in this Agreement
or any other materials presented to Purchaser in connection with the purchase and sale of the
Common Shares and the Warrants constitutes legal, tax or investment advice. Purchaser has
consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Common Shares and the Warrants.

     4.7 Confidentiality. Purchaser will hold in confidence all information concerning this
Agreement and the placement of the Securities hereunder until the earlier of such time as (a) the
Company has made a public announcement concerning the Agreement and the placement of the Securities
hereunder or (b) this Agreement is terminated, except that the obligation of confidentiality shall
not extend to information that (i) is or was already in Purchaser’s possession prior to its being
furnished to the Purchaser by or on behalf of the Company; (ii) has become generally available to
the public other than as a result of a disclosure by Purchaser; (iii) has become available to the
Purchaser on a non-confidential basis from a source other than the Company or its representatives,
and (iv) is requested or required by Purchaser’s advisory clients in connection with the
consummation of this Agreement, which clients are subject to confidentiality agreements as least as
restrictive as those contained in this Agreement.

     4.8 Residency. Purchaser’s executive offices in which its investment decision was made are in
the jurisdiction indicated below such Purchaser’s name on the applicable signature page hereto.

     4.9 Governmental Review. Purchaser understands that no United States federal or state agency
or any other government or governmental agency has passed upon or made any recommendation or
endorsement of the Securities.

 13.

 

     4.10 Legend.

          (a) Purchaser understands that, until such time as the Registration Statement has been
declared effective or the Securities may be sold pursuant to Rule 144 under the Securities Act
(“Rule 144”) without any restriction as to the number of securities as of a particular date that
can then be immediately sold, the Securities may bear a restrictive legend in substantially the
following form (and a stop transfer order may be placed against transfer of the certificates for
the Shares):

     “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE
SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
APPLICABLE SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO
AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.”

          (b) The Company agrees that at such time as such legend is no longer required under this
Section 4.10, it will, no later than three business days following the delivery by a Purchaser to
the Company or the Company’s transfer agent of a certificate representing Common Shares or Warrant
Shares, as applicable, issued with a restrictive legend, deliver or cause to be delivered to such
Purchaser a certificate representing such shares that is free from any legend referring to the
Securities Act. The Company shall not make any notation on its records or give instructions to any
transfer agent of the Company that enlarge the restrictions on transfer set forth in this Section.
Certificates for Securities subject to legend removal hereunder shall be transmitted by the
transfer agent of the Company to the Purchasers by crediting the account of such Purchaser’s prime
broker with the Depository Trust Company. All costs and expenses related to the removal of the
legends and the reissuance of any Securities shall be borne by the Company.

          (c) Each Purchaser, severally and not jointly with the other Purchasers, agrees that the
removal of the restrictive legend from certificates representing Securities as set forth in this
Section 4.10 is predicated upon the Company’s reliance that the Purchaser will sell any Securities
pursuant to either (i) the registration requirements of the Securities Act and such Purchaser shall
have delivered a current prospectus in connection with such sale (if required under the Securities
Act) or such Purchaser shall have confirmed that a current prospectus is deemed to be delivered in
connection with such sale in accordance with Rule 172 under the Securities Act (“Rule 172”) or (ii)
an exemption therefrom.

          (d) The restrictive legend set forth in Section 4.10(a) above shall be removed and the Company
shall issue a certificate without such restrictive legend or any other restrictive legend to the
holder of the applicable shares upon which it is stamped or issue to such holder by electronic
delivery with the applicable balance account at the Depository Trust Company (“DTC”) or in physical
certificated shares, if appropriate, if (i) such Shares are registered for resale under the
Securities Act (provided that, if the Purchaser is selling pursuant to the effective

 14.

 

registration statement registering the Shares for resale, the Purchaser agrees to only sell
such Shares during such time that such registration statement is effective and such Purchaser is
not aware or has not been notified by the Company that such registration statement has been
withdrawn or suspended, and only as permitted by such registration statement); or (ii) such Shares
are sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of the
Company), or (iii) such Shares are eligible for sale without the requirement for the Company to be
in compliance with the current public information required under Rule 144 as to such securities and
without volume or manner-of-sale restrictions. Following the earlier of (i) the effective date of
the Registration Statement or (ii) Rule 144 becoming available for the resale of the Shares,
without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to the Shares and without volume or manner-of-sale restrictions, the
Company shall issue to the Company’s transfer agent the Irrevocable Transfer Agent Instructions
with respect to legend removal consistent with this Section. Any fees (with respect to the
Transfer Agent, the Company’s counsel or otherwise) associated with the issuance of such opinion or
the removal of such legend shall be borne by the Company.

          (e) The Company shall issue irrevocable instructions to its transfer agent, and any subsequent
transfer agent in the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent
Instructions”). The Company represents and warrants that no instruction other than the Irrevocable
Transfer Agent Instructions referred to in this section or instructions that are not contradictory
therewith will be given by the Company to its transfer agent in connection with this Agreement, and
that the Shares shall otherwise be freely transferable on the books and records of the Company as
and to the extent provided in this Agreement and applicable law. The Company acknowledges that a
breach by it of its obligations under this section will cause irreparable harm to a Purchaser.
Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under
this section will be inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this section, that a Purchaser shall be entitled, in addition to all
other available remedies, to an order and/or injunction restraining any breach and requiring
immediate issuance and transfer, without the necessity of showing economic loss and without any
bond or other security being required.

     4.11 Foreign Investors. If Purchaser is not a United States person (as defined by Section
7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it
has satisfied itself as to the full observance of the laws of its jurisdiction in connection with
any invitation to subscribe for the Securities or any use of this Agreement, including (a) the
legal requirements within its jurisdiction for the purchase of the Securities, (b) any foreign
exchange restrictions applicable to such purchase or acquisition, (c) any government or other
consents that may need to be obtained, and (d) the income tax and other tax consequences, if any,
that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities.
Purchaser’s subscription and payment for and continued beneficial ownership of the Securities will
not violate any applicable securities or other laws of Purchaser’s jurisdiction.

 15.

 

ARTICLE 5

Conditions to Closing Obligations of Purchasers

     Each Purchaser’s obligation to purchase the Common Shares and the Warrants at the Closing is,
at the option of such Purchaser, subject to the fulfillment or waiver as of the Closing Date of the
following conditions:

     5.1 Representations and Warranties. The representations and warranties made by the Company in
Article 3 hereof qualified as to materiality shall be true and correct at all times prior to and on
the Closing Date, except to the extent any such representation or warranty expressly speaks as of
an earlier date, in which case such representation or warranty shall be true and correct as of such
earlier date, and the representations and warranties made by the Company in Article 3 hereof not
qualified as to materiality shall be true and correct in all material respects at all times prior
to and on the Closing Date, except to the extent any such representation or warranty expressly
speaks as of an earlier date, in which case such representation or warranty shall be true and
correct in all material respects as of such earlier date.

     5.2 Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Company on or prior to the Closing Date shall have been performed or complied with
in all material respects.

     5.3 Certificates. The Company shall have delivered to the Purchasers duly executed
certificates for the Common Shares and the Warrants (in such denominations as indicated below such
Purchaser’s name on the applicable signature page hereto) and in such nominee names as may be
specified by such Purchaser.

     5.4 Legal Opinion. The Purchasers shall have received on the Closing Date an opinion of
Cooley, counsel for the Company, dated the Closing Date, in substantially the form of Exhibit B.

     5.5 Listing. The Company shall have complied with all requirements with respect to the
listing of the Shares on NASDAQ, except for such requirements not required until after the issuance
of the Shares, such requirements to be complied with promptly after the Closing.

     5.6 Officer’s Certificate. The Company shall have delivered a Certificate, executed on behalf
of the Company by its Chief Executive Officer or Chief Financial Officer, dated as of the Closing
Date, certifying to the fulfillment of the conditions specified in Sections 5.1 and 5.2.

     5.7 Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or
judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any
governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the
transactions contemplated hereby.

     5.8 Secretary’s Certificate. The Company shall have delivered a Certificate, executed on
behalf of the Company by its Secretary, dated as of the Closing Date, certifying the resolutions
adopted by the Board of Directors of the Company (or an authorized committee

 16.

 

thereof) approving the transactions contemplated by this Agreement and the issuance of the
Securities, certifying the current versions of the Restated Certificate and the Bylaws and
certifying as to the signatures and authority of persons signing this Agreement and related
documents on behalf of the Company.

     5.9 Stop Orders. No stop order or suspension of trading shall have been imposed by NASDAQ,
the SEC or any other governmental regulatory body with respect to public trading in the Common
Stock.

ARTICLE 6

Conditions to Closing Obligations of Company

     The Company’s obligation to sell and issue the Common Shares and the Warrants at the Closing
is, at the option of the Company, subject to the fulfillment or waiver as of the Closing Date of
the following conditions:

     6.1 Receipt of Payment. The Purchasers shall have delivered payment of the purchase price to
the Company for the Common Shares and the Warrants being issued hereunder.

     6.2 Representations and Warranties. The representations and warranties made by the Purchasers
in Article 4 hereof qualified as to materiality shall be true and correct at all times prior to and
on the Closing Date, except to the extent any such representation or warranty expressly speaks as
of an earlier date, in which case such representation or warranty shall be true and correct as of
such earlier date, and, the representations and warranties made by the Purchasers in Article 4
hereof not qualified as to materiality shall be true and correct in all material respects at all
times prior to and on the Closing Date, except to the extent any such representation or warranty
expressly speaks as of an earlier date, in which case such representation or warranty shall be true
and correct in all material respects as of such earlier date.

     6.3 Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Purchasers on or prior to the Closing Date shall have been performed or complied
with in all material respects.

     6.4 Delivery of Purchaser Questionnaire. The Company shall have received from each Purchaser
a fully completed Purchaser Questionnaire in the form attached hereto as Exhibit C prior to the
Closing for the Company’s use in preparing the Registration Statement pursuant to Article 7 below.

 17.

 

ARTICLE 7

Covenants

     7.1 Definitions. For the purpose of this Article 7:

          (a) the term “Registration Statement” shall mean any registration statement required to be
filed by Section 7.2 below, and shall include any preliminary prospectus, final prospectus, exhibit
or amendment included in or relating to such registration statements; and

          (b) the term “Registrable Shares” shall mean all of the Common Shares and the Warrant Shares.

     7.2 Registration Procedures and Expenses. The Company shall:

          (a) use its commercially reasonable efforts to file a Registration Statement with the SEC on
or before the date 15 days following the Closing Date (the “Filing Date”) to register the
Registrable Shares on Form S-3 under the Securities Act (providing for shelf registration of such
Registrable Shares under SEC Rule 415) or on such other form which is appropriate to register such
Registrable Shares for resale from time to time by the Purchasers (which, if the Company is not
eligible to use Form S-3, shall include Form S-1); provided, however, that the Company shall give
each Purchaser the opportunity to review and comment on the Registration Statement within a
reasonable period of time prior to its filing; provided further, however, that if a Registration
Statement is not filed with the SEC on or before the Filing Date, then for each 30-day period
following the Filing Date (or any portion thereof), until but excluding the date the Registration
Statement is filed, the Company shall pay each Purchaser, as liquidated damages and not as a
penalty, an amount equal to 2% of the purchase price paid by such Purchaser hereunder, for such
30-day period (or prorated for any portion thereof), and for any such period, such payment shall be
made no later than the first business day of the calendar month next succeeding the last month in
which such period occurs (the parties hereto agreeing that the liquidated damages provided for in
this Section 7.2(a) constitute a reasonable estimate of the damages that may be incurred by the
Purchasers by reason of the failure of the Registration Statement to be filed in accordance with
the provisions hereof); provided further, however, that, notwithstanding anything contained in this
Agreement to the contrary, in the event that the SEC limits the amount of Registrable Shares that
may be included and sold by the Purchasers in the Registration Statement because the SEC deems such
Registration Statement to constitute a primary offering of securities by the Company (in any case,
an “SEC Limitation”), the Company may reduce the number of Registrable Shares included in the
Registration Statement on behalf of the Purchasers, and delay the filing of a Registration
Statement with respect to the Registrable Shares so reduced, as described in Section 7.2(b) below
(provided that the Company shall be obligated to use its commercially reasonable efforts to
advocate with the SEC for the inclusion of all Registrable Shares in the Registration Statement and
provided further that in case of such a reduction of such Registrable Shares, such reduction shall
first reduce Registrable Shares held by affiliates of the Company on a pro rata basis among them
and then reduce Registrable Shares held by other Purchasers on a pro rata basis among them, in each
case in proportion to the respective numbers of Registrable Shares requested to be registered by
each such Purchaser over the total amount of Registrable Shares requested to be registered by all
such Purchasers (it being

 18.

 

understood that the Purchasers shall be entitled to designate which of the Registrable Shares
held by them shall be the subject of any such reduction));

          (b) in the case of an SEC Limitation, include in the Registration Statement the maximum number
of Registrable Shares that can be included therein without causing the Registration Statement to be
deemed to register a primary offering by the Company and use its commercially reasonable efforts at
the first opportunity that is permitted by the SEC, but in no event later than the later of 60 days
from the date substantially all of the Registrable Shares registered under the Registration
Statement have been sold by the Purchasers or six months from the date the Registration Statement
was declared effective (the “Additional Filing Date”), to cause an additional Registration
Statement to become effective for purposes of registering for resale the Registrable Shares that
have been excluded from being registered and in such event, give the Purchasers prompt notice of
the number of the Registrable Shares excluded (the “Additional Registration Statement”). If all
excluded Registrable Shares cannot be registered on the Additional Registration Statement, then the
Company will be obligated to file another Additional Registration Statement as soon as is permitted
by the SEC to cover as many additional excluded Registrable Shares as possible, although the
Company will not be obligated to file any more than three Additional Registration Statements for
excluded Registrable Shares. The Company’s obligations under this Agreement with respect to such
Additional Registration Statements shall be the same as its obligations for the original
Registration Statement, provided that the “Filing Date” for such Additional Registration Statements
shall be the Additional Filing Date, and the “Effectiveness Deadline Date” (as defined below) for
such Additional Registration Statement shall be delayed by the number of days that elapses between
the Filing Date and Additional Filing Date;

          (c) use its commercially reasonable efforts, subject to receipt of necessary information from
the Purchasers, to cause any such Registration Statement filed pursuant to Section 7.2(a) above to
become effective as promptly after filing of such Registration Statement as practicable but in any
event by the date (the “Effectiveness Deadline Date”) that is 60 days following the Closing Date;
provided, however, that in the event that such Registration Statement is reviewed by the SEC, then
the Effectiveness Deadline Date shall mean, with respect to any Registration Statement, the date
that is 90 days following the Closing Date; provided, however, that if the Registration Statement
is not declared effective by the SEC on or prior to the Effectiveness Deadline Date, then for each
30-day period following the Effectiveness Deadline Date (or any portion thereof), until but
excluding the date the Registration Statement is declared effective, the Company shall pay each
Purchaser, as liquidated damages and not as a penalty, an amount equal to 2% of the purchase price
paid by such Purchaser hereunder, for such 30-day period (or prorated for any portion thereof), and
for any such period, such payment shall be made no later than the first business day of the
calendar month next succeeding the last month in which such period occurs (the parties hereto
agreeing that the liquidated damages provided for in this Section 7.2(c) constitute a reasonable
estimate of the damages that may be incurred by the Purchasers by reason of the failure of the
Registration Statement to be declared effective in accordance with the provisions hereof);

          (d) prepare and file with the SEC such amendments and supplements to such Registration
Statement and the prospectus used in connection therewith as may be necessary to keep such
Registration Statement continuously effective until termination of such obligation as

 19.

 

provided in Section 7.6 below, subject to the Company’s right to suspend pursuant to
Section 7.4;

          (e) respond as promptly as reasonably practicable to any comments received from the SEC with
respect to such Registration Statement and prospectus or any amendments thereto and prepare and
file with the SEC such amendments and supplements to such Registration Statement and the prospectus
used in connection therewith (i) as may be necessary to keep such Registration Statement
continuously effective until termination of such obligation as provided in Section 7.6 below,
subject to the Company’s right to suspend pursuant to Section 7.4, (ii) so that no Registration
Statement nor any prospectus will contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein (in the
case of any prospectus, form of prospectus or supplement thereto, in light of the circumstances
under which they were made), not misleading; or (iii) as requested by a Purchaser and as the
Company reasonably agrees should be made thereby;

          (f) file such documents as may be required of the Company for normal securities law clearance
for the resale of the Registrable Shares in such states of the United States as may be reasonably
requested by each Purchaser; provided, however, that the Company shall not be required in
connection with this paragraph (f) to qualify as a foreign corporation or execute a general consent
to service of process in any jurisdiction;

          (g) upon notification by the SEC that that the Registration Statement will not be reviewed or
is not subject to further review by the SEC, the Company shall within one business day following
the date of such notification request acceleration of such Registration Statement;

          (h) upon notification by the SEC that that the Registration Statement has been declared
effective by the SEC, the Company shall file the final prospectus under Rule 424 of the Securities
Act (“Rule 424”) within the applicable time period prescribed by Rule 424;

          (i) advise each Purchaser promptly:

               (i) of the effectiveness of the Registration Statement or any post-effective amendments
thereto;

               (ii) of any request by the SEC for amendments to the Registration Statement or amendments to
the prospectus or for additional information relating thereto or any notification by the SEC that
there will be a “review” of the Registration Statement and of any comments that pertain to the
Purchaser and all written responses thereto;

               (iii) of the issuance by the SEC of any stop order suspending the effectiveness of the
Registration Statement under the Securities Act or of the suspension by any state securities
commission of the qualification of the Registrable Shares for offering or sale in any jurisdiction,
or the initiation of any proceeding for any of the preceding purposes; and

               (iv) of the existence of any fact and the happening of any event that makes any statement of a
material fact made in the Registration Statement, the prospectus and

 20.

 

amendment or supplement thereto, or any document incorporated by reference therein, untrue, or
that requires the making of any additions to or changes in the Registration Statement or the
prospectus in order to make the statements therein not misleading;

          (j) use its commercially reasonable efforts to cause all Registrable Shares to be listed on
each securities exchange, if any, on which equity securities by the Company are then listed;

          (k) use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain
the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii)
any suspension of the qualification (or exemption from qualification) of any of the Registrable
Securities for sale in any jurisdiction, as soon as practicable;

          (l) bear all expenses in connection with the procedures in paragraphs (a) through (j) of this
Section 7.2 and the registration of the Registrable Shares on such Registration Statement and the
satisfaction of the blue sky laws of such states;

          (m) not include securities of the Company other than the Registrable Shares in a Registration
Statement and the Company shall not prior to the Closing Date enter into any agreement providing
any such right to any of its security holders. The Company shall not, from the date hereof until
the date that is 60 days after the date of the effectiveness of the Registration Statement, prepare
and file with the SEC a registration statement relating to an offering for its own account under
the Securities Act of any of its equity securities, other than (i) a registration statement on Form
S-8, (ii) in connection with an acquisition, on Form S-4, (iii) in connection with the Registration
Statement on Form S-1 filed with the SEC on September 9, 2009 (File No. 333-161804) or (iv) a
registration statement to register for resale securities issued by the Company pursuant to
acquisitions or strategic transactions approved by a majority of the disinterested directors of the
Company, provided that any such issuance shall only be to a Person which is, itself or through its
subsidiaries, an operating company in a business synergistic with the business of the Company and
in which the Company receives benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of
raising capital or to an entity whose primary business is investing in securities. For the
avoidance of doubt, the Company shall not be prohibited from preparing and filing with the SEC a
registration statement relating to an offering of Common Stock by existing stockholders of the
Company under the Securities Act pursuant to the terms of existing registration rights held by such
stockholder or from filing amendments to registration statements filed prior to the date of this
Agreement;

          (n) use its commercially reasonable efforts to maintain eligibility for use of Form S-3
promulgated under the Securities Act or such other form which is appropriate to register such
Shares for resale from time to time by the Purchasers (which, if the Company is not eligible to use
Form S-3, shall include Form S-1); and

          (o) in the event that Form S-3 is not available for the registration of the resale of the
Registrable Shares hereunder, undertake to register the Registrable Shares on Form S-3 as soon as
such form is available, provided that the Company shall maintain the effectiveness of the

 21.

 

Registration Statement then in effect until such time as a Registration Statement on Form S-3
covering the Registrable Securities has been declared effective by the SEC;

     7.3 Indemnification.

          (a) The Company agrees to indemnify and hold harmless each Purchaser, the affiliates,
partners, members, officers and directors of each Purchaser and each person, if any, who controls
such Purchaser within the meaning of the Securities Act or the Exchange Act (each, a “Purchaser
Party”), from and against any losses, claims, damages or liabilities to which they may become
subject (under the Securities Act or otherwise) insofar as such losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, any
material breach of this Agreement by the Company or any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement or any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading or
arise out of any failure by the Company to fulfill any undertaking included in the Registration
Statement or arise out of or are based upon any action instituted against a Purchaser Party in any
capacity, or any of them or their respective affiliates, by any stockholder of the Company who is
not an affiliate of such Purchaser Party, and the Company will, as incurred, reimburse such
Purchaser Party for any legal or other expenses reasonably incurred in investigating, defending or
preparing to defend any such action, proceeding or claim; provided, however, that the Company shall
not be liable in any such case to the extent that such loss, claim, damage or liability
(collectively, “Loss”) arises out of, or is based upon, an untrue statement or omission or alleged
untrue statement or omission made in such Registration Statement only in reliance upon and in
conformity with written information furnished to the Company by or on behalf of such Purchaser
Party specifically for use in preparation of the Registration Statement or any breach of this
Agreement by such Purchaser; provided further, however, that the Company shall not be liable to any
Purchaser of Registrable Shares (or any affiliate partner, member, officer, director or controlling
person of such Purchaser) to the extent that any such Loss is caused by an untrue statement or
omission or alleged untrue statement or omission made in any preliminary prospectus if either (i)
(A) such Purchaser failed to send or deliver a copy of the final prospectus with or prior to, or
such Purchaser failed to confirm that a final prospectus was deemed to be delivered prior to (in
accordance with Rule 172), the delivery of written confirmation of the sale by such Purchaser to
the person asserting the claim from which such Loss resulted and (B) the final prospectus corrected
such untrue statement or omission, (ii) (X) such untrue statement or omission is corrected in an
amendment or supplement to the prospectus and (Y) having previously been furnished by or on behalf
of the Company with copies of the prospectus as so amended or supplemented or notified by the
Company that such amended or supplemented prospectus has been filed with the SEC, in accordance
with Rule 172, such Purchaser thereafter fails to deliver such prospectus as so amended or
supplemented, with or prior to, or such Purchaser fails to confirm that the prospectus as so
amended or supplemented was deemed to be delivered prior to (in accordance with Rule 172), the
delivery of written confirmation of the sale of a Registrable Share to the person asserting the
claim from which such Loss resulted or (iii) such Purchaser sold Registrable Shares in violation of
such Purchaser’s covenant contained in Section 7.4 of this Agreement.

 22.

 

          (b) Each Purchaser, severally and not jointly, agrees to indemnify and hold harmless the
Company (and each person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, each officer of the Company who signs the
Registration Statement and each director of the Company), from and against any losses, claims,
damages or liabilities to which the Company (or any such officer, director or controlling person)
may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages
or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, any
material breach of this Agreement by such Purchaser or any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement or any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading in
each case, on the effective date thereof, if, and only to the extent, such untrue statement or
omission or alleged untrue statement or omission was made in sole reliance upon and in conformity
with written information furnished by or on behalf of such Purchaser specifically for use in
preparation of the Registration Statement, and such Purchaser will reimburse the Company (and each
of its officers, directors or controlling persons) for any legal or other expenses reasonably
incurred in investigating, defending or preparing to defend any such action, proceeding or claim;
provided, however, that in no event shall any indemnity under this Section 7.3(b) be greater in
amount than the dollar amount of the proceeds (net of (i) the purchase price of the Registrable
Shares included in the Registration Statement giving rise to such indemnification obligation and
(ii) the amount of any damages such Purchaser has otherwise been required to pay by reason of such
untrue statement or omission or alleged untrue statement or omission) received by such Purchaser
upon the sale of such Registrable Shares.

          (c) Promptly after receipt by any indemnified person of a notice of a claim or the beginning
of any action in respect of which indemnity is to be sought against an indemnifying person pursuant
to this Section 7.3, such indemnified person shall notify the indemnifying person in writing of
such claim or of the commencement of such action, and, subject to the provisions hereinafter
stated, in case any such action shall be brought against an indemnified person and such
indemnifying person shall have been notified thereof, such indemnifying person shall be entitled to
participate therein, and, to the extent that it shall wish, to assume the defense thereof, with
counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying
person to such indemnified person of its election to assume the defense thereof, such indemnifying
person shall not be liable to such indemnified person for any legal expenses subsequently incurred
by such indemnified person in connection with the defense thereof without the authorization of the
indemnifying person; provided, however, that if there exists or shall exist a conflict of interest
that would make it inappropriate in the reasonable judgment of the indemnified person for the same
counsel to represent both the indemnified person and such indemnifying person or any affiliate or
associate thereof, the indemnified person shall be entitled to retain its own counsel at the
expense of such indemnifying person; provided, further, that no indemnifying person shall be
responsible for the fees and expense of more than one separate counsel for all indemnified parties.
The indemnifying party shall not settle an action without the consent of the indemnified party,
which consent shall not be unreasonably withheld.

          (d) If after proper notice of a claim or the commencement of any action against the
indemnified party, the indemnifying party does not choose to participate, then the

 23.

 

indemnified party shall assume the defense thereof and upon written notice by the indemnified
party requesting advance payment of a stated amount for its reasonable defense costs and expenses,
the indemnifying party shall advance payment for such reasonable defense costs and expenses (the
“Advance Indemnification Payment”) to the indemnified party. In the event that the indemnified
party’s actual defense costs and expenses exceed the amount of the Advance Indemnification Payment,
then upon written request by the indemnified party, the indemnifying party shall reimburse the
indemnified party for such difference; in the event that the Advance Indemnification Payment
exceeds the indemnified party’s actual costs and expenses, the indemnified party shall promptly
remit payment of such difference to the indemnifying party.

          (e) If the indemnification provided for in this Section 7.3 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages
or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified
party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or
payable by such indemnified party as a result of such loss, claim, damage or liability in such
proportion as is appropriate to reflect the relative fault of the indemnifying party on the one
hand and of the indemnified party on the other, as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by an indemnifying party
hereunder be greater in amount than the dollar amount of the proceeds (net of (i) the purchase
price of the Registrable Shares included in the Registration Statement giving rise to such
indemnification obligation and (ii) the amount of any damages such indemnifying party has otherwise
been required to pay by reason of such untrue statement or omission or alleged untrue statement or
omission) received by such indemnifying party upon the sale of such Registrable Shares.

     7.4 Prospectus Delivery and Suspension of Registration. Each Purchaser hereby covenants with
the Company not to make any sale of the Registrable Shares without complying with Section 8.2. The
Purchaser acknowledges that there may be times when the Company must suspend the use of the
prospectus forming a part of the Registration Statement until such time as an amendment to the
Registration Statement has been filed by the Company and declared effective by the SEC, or until
such time as the Company has filed an appropriate report with the SEC pursuant to the Exchange Act.
Each Purchaser hereby covenants that it will not sell any Registrable Shares pursuant to said
prospectus during the period commencing at the time at which the Company gives such Purchaser
notice of the suspension of the use of said prospectus and ending at the time the Company gives
such Purchaser notice that such Purchaser may thereafter effect sales pursuant to said prospectus;
provided, that such suspension periods shall in no event exceed 30 days in any 12 month period and
that, in the good faith judgment of the Company’s Board of Directors, the Company would, in the
absence of such delay or suspension hereunder, be required under state or federal securities laws
to disclose any corporate development, a potentially significant transaction or event involving the
Company, or any negotiations, discussions, or proposals directly relating thereto, in either case
the disclosure of which would reasonably be expected to have a material adverse effect upon the
Company or its stockholders; provided further, that the Company may suspend the use of the
prospectus forming a part of the Registration Statement to the extent necessary to file any
post-effective amendment to the Registration Statement in order to amend the table of selling
stockholders within the Registration Statement to reflect transfers of the Securities pursuant to
Sections 8.2(a) and 8.2(b). The Company shall promptly (i) notify the Purchasers in writing of the
existence of material

 24.

 

non-public information giving rise to such suspension (provided that the Company shall not
disclose the content of such material non-public information to the Purchasers) or the need to file
a post-effective amendment, as applicable, and the date on which such suspension will begin, (ii)
use commercially reasonable efforts to terminate a suspension as promptly as practicable and (iii)
notify the Purchasers in writing of the date on which the suspension ends. If, after the
Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to
such Registration Statement, except as excused pursuant to this Section 7.4, then for each 30-day
period following the date sales cannot be made pursuant to such Registration Statement (or any
portion thereof), until but excluding the date sales can again be made pursuant to such
Registration Statement, the Company shall pay each Purchaser, as liquidated damages and not as a
penalty, an amount equal to 2% of the purchase price paid by such Purchaser hereunder, for such
30-day period (or prorated for any portion thereof), and for any such period, such payment shall be
made no later than the first business day of the calendar month next succeeding the last month in
which such period occurs (the parties hereto agreeing that the liquidated damages provided for in
this Section 7.4 constitute a reasonable estimate of the damages that may be incurred by the
Purchasers by reason of the failure of the Registration Statement to remain effective in accordance
with the provisions hereof).

     7.5 Termination of Obligations. The obligations of the Company pursuant to Section 7.2 hereof
shall cease and terminate upon the earlier to occur of (a) such time as all of the Registrable
Shares have been resold, or (b) with respect to any Purchaser, such time as all of the Registrable
Shares held by such Purchaser may be freely resold pursuant to Rule 144 without the requirement for
the Company to be in compliance with the current public information required under Rule 144 and
without volume or manner-of-sale restrictions as to the Registrable Shares held by such Purchaser.

     7.6 Reporting Requirements.

          (a) With a view to making available the benefits of certain rules and regulations of the SEC
that may at any time permit the sale of the Securities to the public without registration or
pursuant to a registration statement on Form S-3, the Company agrees to use its commercially
reasonable efforts to:

               (i) make and keep public information available, as those terms are understood and defined in
Rule 144;

               (ii) file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and

               (iii) so long as any of the Purchasers own Registrable Shares, to furnish to such Purchaser
upon request (A) a written statement by the Company as to whether it is in compliance with the
reporting requirements of Rule 144, the Securities Act and the Exchange Act, or whether it is
qualified as a registrant whose securities may be resold pursuant to SEC Form S-3 and (B) a copy of
the most recent annual or quarterly report of the Company and such other reports and documents so
filed by the Company.

 25.

 

          (b) For each 30-day period during which the Company fails to make and keep public information
available pursuant to Section 7.6(a)(i) above in the period commencing with the date that is six
months from the Closing Date and ending with the first anniversary of the Closing Date, until but
excluding the date the Company regains compliance with such Section, the Company shall pay each
Purchaser, as liquidated damages and not as a penalty, an amount equal to 2% of the purchase price
paid by such Purchaser hereunder, for such 30-day period (or prorated for any portion thereof), and
for any such period, such payment shall be made no later than the first business day of the
calendar month next succeeding the last month in which such period occurs (the parties hereto
agreeing that the liquidated damages provided for in this Section 7.6(b) constitute a reasonable
estimate of the damages that may be incurred by the Purchasers by reason of the failure of the
Company to make and keep public information available during such six month period in accordance
with the provisions hereof).

     7.7 Blue Sky. The Company agrees to timely file a Form D with respect to the Shares as
required under Regulation D. The Company shall obtain and maintain all necessary blue sky law
permits and qualifications, or secured exemptions therefrom, required by any state for the offer
and sale of Securities.

     7.8 Press Release. On or before 9:30 a.m., New York Time, on the first business day following
the date that the Purchasers have entered into this Agreement, the Company shall issue a press
release concerning this Agreement and the transactions contemplated hereby, and shall use its
commercially reasonable efforts to file a Current Report on Form 8-K regarding such matters as soon
as is practicable thereafter, which filing shall in any event be completed prior to 5:30 p.m., New
York Time, on the date of the issuance of such press release.

     7.9 Non-Public Information. Except with respect to the material terms and conditions of the
transactions contemplated by this Agreement, and except with the express written consent of such
Purchaser and unless prior thereto such Purchaser shall have executed a written agreement regarding
the confidentiality and use of such information, the Company shall not, and shall cause each
Subsidiary and each of their respective officers, directors, employees and agents, not to, and each
Purchaser shall not directly solicit the Company, any of its Subsidiaries or any of their
respective officers, directors, employees or agents to provide any Purchaser with any material,
non-public information regarding the Company or any of its Subsidiaries from and after the filing
of the press release(s) referred to herein.

ARTICLE 8

Restrictions on Transferability of Securities;

Compliance with Securities Act

     8.1 Restrictions on Transferability. The Securities shall not be transferable in the absence
of a registration under the Securities Act or an exemption therefrom. The Company shall be entitled
to give stop transfer instructions to its transfer agent with respect to the Securities in order to
enforce the foregoing restrictions.

 26.

 

     8.2 Transfer of Securities.

          (a) Each Purchaser hereby covenants with the Company not to make any sale of the Securities
except:

               (i) in accordance with the Registration Statement, in which case such Purchaser shall have
delivered a current prospectus in connection with such sale (if required under the Securities Act)
or such Purchaser shall have confirmed that a current prospectus is deemed to be delivered in
connection with such sale in accordance with Rule 172; or

               (ii) in accordance with Rule 144, in which case such Purchaser covenants to comply with
Rule 144; or

               (iii) (A) If the transferee has agreed in writing to be bound by the terms of this Agreement
and (B) such Purchaser shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require registration of such shares
under the Securities Act.

          (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to
a transfer by a Purchaser that is (i) a partnership transferring to its partners or former partners
in accordance with partnership interests, (ii) a corporation transferring to a wholly-owned
subsidiary or a parent corporation that owns all of the capital stock of the Purchaser, (iii) a
limited liability company transferring to its members or former members in accordance with their
interest in the limited liability company or (iv) an individual transferring to the Purchaser’s
family member or trust for the benefit of an individual Purchaser and/or the Purchaser’s family
member; provided that in each case the transferee will agree in writing to be subject to the terms
of this Agreement to the same extent as if such transferee were an original Purchaser hereunder.

     8.3 Purchaser Information. Each Purchaser covenants that it will promptly notify the Company
of any change in the information set forth in the Registration Statement regarding such Purchaser
or such Purchaser’s “Plan of Distribution,” to the extent such change is required to be disclosed
under applicable federal securities laws.

ARTICLE 9

Miscellaneous

     9.1 Termination.

          (a) This Agreement may be terminated and the sale and purchase of the Common Shares and the
Warrants abandoned at any time prior to the Closing, by written notice of any individual Purchaser,
if the Closing has not occurred within five business days of the date hereof (other than as a
result of the failure on the part of the party giving such notice of termination to perform its
covenants and obligations under this Agreement in all material respects); provided, however, that
the abandonment of the sale and purchase of the Common Shares and the Warrants shall be applicable
only to such Purchaser providing such written notice.

 27.

 

          (b) If this Agreement is terminated pursuant to this Section 9.1 all further obligations of
the Company to such Purchaser and of such Purchaser shall terminate; provided, however, that (i) no
party shall be relieved of any liability arising from any breach by such party of any provision of
this Agreement and (ii) the parties shall, in all events, remain bound by and continue to be
subject to the provisions set forth in this Article 9.

     9.2 Waivers and Amendments. The terms of this Agreement may be waived or amended with the
written consent of the Company and each Purchaser; provided, however, that with respect to Article
7 hereof, the terms of this Agreement may be waived or amended with the written consent of the
Company and the record holders of at least two-thirds of the Registrable Shares and any such
amendment or waiver shall be binding upon the Company and all holders of Registrable Shares;
provided further, that any amendment pursuant to this Section 9.2 that would adversely affect the
rights of any Purchaser in a manner different than the rights of other Purchasers shall also
require the written consent of such Purchaser.

     9.3 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each
Purchaser under this Agreement are several and not joint with the obligations of any other
Purchaser, and no Purchaser shall be responsible in any way for the representations and warranties
of, or the performance of the obligations of any other Purchaser under this Agreement. Nothing
contained herein and no action taken by any Purchaser pursuant thereto, shall be deemed to
constitute the Purchasers as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Purchasers are in any way acting in concert or as a group,
or are deemed affiliates (as such term is defined under the Exchange Act) with respect to such
obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled
to independently protect and enforce its rights, including without limitation the rights arising
out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an
additional party in any proceeding for such purpose.

     9.4 Governing Law. This Agreement shall be governed in all respects by and construed in
accordance with the laws of the State of New York without any regard to conflicts of laws
principles.

     9.5 Survival. The representations, warranties, covenants and agreements made in this
Agreement shall survive any investigation made by the Company or the Purchasers and the Closing.

     9.6 Successors and Assigns. The provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of the parties to this
Agreement. Upon a permitted transfer of a Purchaser’s Securities on the books of the Company in
accordance with the terms of Sections 8.2(a)(iii) or 8.2(b), the Purchaser may assign this
Agreement to the permitted transferee upon prior written notice to the Company. Except as set
forth in the previous sentence, no Purchaser shall assign this Agreement without the prior written
consent of the Company.

     9.7 Entire Agreement; No Inconsistent Agreements. This Agreement (including all schedules and
exhibits hereto) constitutes the full and entire understanding and agreement between the parties
with regard to the subjects thereof. Neither the Company nor any of its

 28.

 

Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its
Subsidiaries, on or after the date hereof, enter into any agreement with respect to its securities,
that would have the effect of impairing the rights granted to the Purchasers in this Agreement or
otherwise conflicts with the provisions hereof.

     9.8 Notices, etc. All notices and other communications required or permitted under this
Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to
the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal
business hours of the recipient, if not, then on the next business day, (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one
day after deposit with a nationally recognized overnight courier, specifying next day delivery,
with written verification of receipt. All communications shall be sent to the Company or the
Purchasers, as the case may be, at their respective addresses set forth at the beginning of this
Agreement or indicated below such Purchaser’s name on the applicable signature page hereto, as
appropriate, or at such other address as the Company or the Purchasers may designate by 10 days
advance written notice to the other party.

     9.9 Severability of this Agreement. If any provision of this Agreement shall be judicially
determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

     9.10 Counterparts; Facsimile. This Agreement may be executed in any number of counterparts,
each of which shall be an original, but all of which together shall constitute one instrument.
Facsimile signatures shall be treated the same as original signatures.

     9.11 Further Assurances. Each party to this Agreement shall do and perform or cause to be
done and performed all such further acts and things and shall execute and deliver all such other
agreements, certificates, instruments and documents as the other party hereto may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.

     9.12 Currency. All references to “dollars” or “$” in this Agreement shall be deemed to refer
to United States dollars.

     9.13 Waiver of Conflicts. Each party to this Agreement acknowledges that legal counsel for
the Company, Cooley, has in the past and may continue in the future to perform legal services for
one or more of the Purchasers or their affiliates in matters unrelated to the transactions
contemplated by this Agreement, including, but not limited to, the representation of the Purchasers
in matters of a similar nature to the transactions contemplated herein. Each party to this
Agreement hereby: (a) acknowledges that it has had an opportunity to ask for and have obtained
information relevant to such representation, including disclosure of the reasonably foreseeable
adverse consequences of such representation; (b) acknowledges that with respect to the transactions
contemplated herein, Cooley has represented the Company and not any individual Purchaser or any
individual stockholder, director or employee of the Company; and (c) gives its informed consent to
Cooley’s representation of the Company in the transactions contemplated by this Agreement.

 29.

 

     9.14 Acknowledgement Regarding RBC. Each Purchaser acknowledges that RBC is acting as a
placement agent for the Securities being offered hereby and will be compensated by the Company for
acting in such capacity. Each Purchaser further acknowledges that RBC has acted solely as agent of
the Company in connection with the offering of the Securities by the Company. Each Purchaser
further acknowledges that the provisions of Section 4.5 and this Section 9.14 are for the benefit
of and may be enforced by RBC.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 30.

 

     In Witness Whereof, the undersigned has caused its duly authorized officer to execute
this Agreement as of the date first above written.

	 	 	 	 	 
	 	Alexza Pharmaceuticals, Inc.

 	 
	 	By:  	/s/ August J. Moretti
 	 
	 	 	August J. Moretti 	 
	 	 	Senior Vice President and Chief Financial Officer 	 
	 

[Signature Page to Securities Purchase Agreement]

 

 

     In Witness Whereof, the undersigned has caused its duly authorized officer to execute
this Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	Wasatch Funds, Inc.

for Wasatch Small Cap Growth Fund	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Michael Yeates
 

Name: Michael Yeates
	 	 
	 

	 	 	 	Title: Vice President of Wasatch Advisors, Inc., 

Investment Advisor for Wasatch Funds, Inc.	 	 

	 	 	 	 	 	 	 
	 	 	Minnesota
	 	 
	 	 	 	 	 
	 	 	Jurisdiction of organization of entity
	 	 
	 
	 	 	 	 	 	 
	 

	 	Address:
	 	150 Social Hall Ave., 4th Floor	 	 
	 

	 	 	 	Salt Lake City, UT 84111	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $995,867.95
	 	409,401
	 	368,461       

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Wasatch Funds, Inc.

for Wasatch Ultra Growth Fund
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Michael Yeates	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Michael Yeates	 	 
	 

	 	 	 	Title: Vice President of Wasatch Advisors, Inc.,	 	 
	 

	 	 	 	Investment Advisor for Wasatch Funds, Inc.	 	 
	 
	 	 	 	 	 	 
	 	 	Minnesota	 	 
	 	 	 	 	 
	 	 	Jurisdiction of organization of entity	 	 

	 	 	 	 	 
	 

	 	Address:
	 	150 Social Hall Ave., 4th Floor
	 

	 	 	 	Salt Lake City, UT 84111

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $184,308.08
	 	 	75,769	 	 	 	68,192	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Wasatch Funds, Inc.

for Wasatch Micro Cap Fund
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Michael Yeates	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Michael Yeates	 	 
	 

	 	 	 	Title: Vice President of Wasatch Advisors, Inc.,	 	 
	 

	 	 	 	Investment Advisor for Wasatch Funds, Inc.	 	 
	 
	 	 	 	 	 	 
	 	 	Minnesota
	 	 	 	 	 
	 	 	Jurisdiction of organization of entity

	 	 	 	 	 
	 

	 	Address:
	 	150 Social Hall Ave., 4th Floor
	 

	 	 	 	Salt Lake City, UT 84111

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $794,962.88
	 	 	326,809	 	 	 	294,128	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Abingworth Bioventures V L.P.
	 
	 	 	 	 	 	 
	 

	 	By:	 	Abingworth LLP	 	 
	 

	 	Its:
	 	Manager	 	 
	 
	 

	 	By:	 	/s/ James Abell	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Name: James Abell	 	 
	 

	 	 	 	Title: Partner	 	 
	 
	 
	 	 	 	          England	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: 38 Jermyn Street	 	 
	 
	 	 	 	         London	 	 
	 
	 	 	 	         SW1Y 6DN	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $2,096,982.83
	 	 	862,069	 	 	 	775,862	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Abingworth Bioequities Master Fund Limited
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ James Abell	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: James Abell	 	 
	 

	 	 	 	Title: Authorized Signatory	 	 
	 
	 
	 	 	 	Cayman Islands	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 

	 	 	 	 	 	 	 
	 	 	 Registered
Address:	 	PO Box 309 GT

England House

South Church Street, George Town

Grand Cayman, Cayman Islands
	 	 	 	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $1,048,490.26
	 	 	431,034	 	 	 	387,931	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Azimuth Opportunity, Ltd.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Peter W. Poole	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Peter W. Poole	 	 
	 
	 	 	 	Title: Director	 	 
	 
	 
	 	 	 	British Virgin Islands	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: Folio House, Walter James Francis Drive,	 	 
	 
	 	 	 	        P.O. Box 800, Road Town, Tortola, British Virgin 	 	 
	 
	 	 	 	        Islands, VG 1110	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $3,709,563
	 	 	1,525,000	 	 	 	1,372,500	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Federated Kaufmann Fund,

a portfolio of Federated Equity Funds
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Lawrence Auriana	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Lawrence Auriana	 	 
	 

	 	 	 	Title: Vice President, Global Investment Management, as attorney-in-fact for Federated Kaufmann Fund, a portfolio of Federated Equity Funds

	 	 
	 
	 	 	 	             Massachusetts	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 

	 	 	 	 	 	 	 
	 	 	Address:	140 East
45th St.	 
	 	 	 
	 
	 
	 
	 	 	 	 	NY, NY 10017	  
	 	 	 	 
	 
	 
	 	 	 	 	 	 
	 	 	 	 
	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $1,034,885.25
	 	 	425,441	 	 	 	382,897	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Federated Kaufmann Fund II,

a portfolio of Federated Equity Funds
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Aash M. Shah	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: 	Aash M. Shah
	 

	 	 	 	Title:	Vice President, Federated Global
Investment Management, as attorney-in-fact for Federated Kaufmann
Fund II, a portfolio of Federated Insurance Series
	 
	 	 	 	 	 	 
	 
	 	 	 	Massachusetts	 
	 	 	 	 
	 

	 	 	Jurisdiction of organization of entity	 
	 
	 	 	 	 	 	 
	 	 	Address:	140 East
45th St.	 
	 	 	 
	 
	 
	 
	 	 	 	 	NY, NY 10017	  
	 	 	 	 
	 
	 
	 	 	 	 	 	 
	 	 	 	 
	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase
Price $13,605.01
	 	 	5,593	 	 	 	5,034	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	BB Alpha Health
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Patrick Harrigan	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name:  Patrick Harrigan	 	 
	 

	 	 	 	Title:  Director	 	 
	 
	 
	 	 	 	Cayman Islands	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address:  87 Mary Street	 	 
	 
	 	 	 	         George Town, Grand Cayman	 	 
	 
	 	 	 	         Cayman Islands KY1-9002	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $209,699
	 	 	86,207	 	 	 	77,586	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	T. Rowe Price Associates, Inc., 

Investment Adviser By and on Behalf of its Advisory

Accounts Listed on Attachment A
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Jay Markowitz	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Jay Markowitz	 	 
	 

	 	 	 	Title: Vice President	 	 
	 
	 

	 	 	 	          Maryland, U.S.

	 	 
	 	 	 	 	 
	 

	 	 	 	          
Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: T. Rowe Price Associates, Inc.

                 100 East Pratt Street 
                 Baltimore, MD 21202

Attn:       
Andrew Baek 

                 Vice President and Senior
Legal Counsel	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $2,444,419.25
	 	 	1,004,900	 	 	 	904,410	 

[By and On Behalf of the Funds and Accounts as set forth on Attachment A]

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	The Conus Fund L.P.
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Mathew Lazarus 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	Name: Mathew Lazarus	 	 
	 

	 	 	 	Title: Vice President	 	 
	 
	 
	 	 	 	New York 	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: c/o Conus Partners Inc.	 	 
	 
	 	 	 	         49 W. 38th St, 11th Floor 
	 
	 	 	 	         New York, NY 10018 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $383,848.50
	 	 	157,800	 	 	 	142,020	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	The Conus Fund Offshore Master Fund Ltd. 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Mathew Lazarus 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mathew Lazarus	 	 
	 

	 	 	 	Title: Vice President	 	 
	 
	 
	 	 	 	Cayman Islands	 	 
	 	 	 	 	 
	 

	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: c/o Conus Partners Inc.	 	 
	 
	 	 	 	         49 W. 38th St, 11th Floor 
	 
	 	 	 	         New York, NY 10018 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $83,434.75
	 	 	34,300	 	 	 	30,870	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	The Conus Fund (QP) L.P.
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Mathew Lazarus 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mathew Lazarus	 	 
	 

	 	 	 	Title: Vice President	 	 
	 
	 
	 	 	 	New York 	 	 
	 	 	 	 	 
	 
	 	 	 	Jurisdiction of organization of entity	 	 
	 
	 	 	 	 	 	 
	 	 	Address: c/o Conus Partners Inc.	 	 
	 
	 	 	 	         49 W. 38th St, 11th Floor
	 
	 	 	 	         New York, NY 10018

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $530,041.75
	 	 	217,900	 	 	 	196,110	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	CADUCEUS CAPITAL MASTER FUND LIMITED
	 
	 	 	 	 
	 
	 	By:	 	/s/ Samuel D. Isaly
	 
	 	 	 	 
	 
	 	 	 	Name: Samuel D. Isaly
	 
	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          Bermuda
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 
	 	Address:	 	c/o OrbiMed Advisors LLC
	 
	 	 	 	767 Third Avenue, 30th Fl
	 
	 	 	 	New York, NY 10017

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $900,025
	 	 	370,000	 	 	 	333,000	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	CADUCEUS CAPITAL II, L.P.
	 
	 	 	 	 
	 
	 	By:
	 	/s/ Samuel D. Isaly
	 
	 	 	 	 
	 
	 	 	 	Name: Samuel D. Isaly
	 
	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          Delaware
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 
	 	Address:
	 	c/o OrbiMed Advisors LLC
	 
	 	 	 	767 Third Avenue, 30th Fl
	 
	 	 	 	New York, NY 10017

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $608,125
	 	 	250,000	 	 	 	225,000	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	UBS EUCALYPTUS FUND, L.L.C.
	 
	 	 	 	 
	 
	 	By:
	 	/s/ Samuel D. Isaly
	 
	 	 	 	 
	 
	 	 	 	Name: Samuel D. Isaly
	 
	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          Delaware
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 
	 	Address:
	 	c/o OrbiMed Advisors LLC
	 
	 	 	 	767 Third Avenue, 30th Fl 

	 
	 	 	 	New York, NY 10017

     Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $656,775
	 	 	270,000	 	 	 	243,000	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	PW EUCALYPTUS FUND, LTD.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ Samuel D. Isaly
	 

	 	 	 	 
	 

	 	 	 	Name: Samuel D. Isaly
	 

	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          Cayman Islands
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 

	 	Address:
	 	c/o OrbiMed Advisors LLC
	 

	 	 	 	767 Third Avenue, 30th Fl
	 

	 	 	 	New York, NY 10017

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $58,380
	 	 	24,000	 	 	 	21,600	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	SUMMER STREET LIFE SCIENCES HEDGE
	 	 	FUND INVESTORS LLC
	 
	 	 	 	 
	 
	 	By:	 	/s/ Samuel D. Isaly
	 
	 	 	 	 
	 
	 	 	 	Name: Samuel D. Isaly
	 
	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          Delaware
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 
	 	Address:	 	c/o OrbiMed Advisors LLC
	 
	 	 	 	767 Third Avenue, 30th Fl
	 
	 	 	 	New York, NY 10017

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $301,630
	 	 	124,000	 	 	 	111,600	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 	 	THE BIOTECH GROWTH TRUST PLC
	 
	 	 	 	 
	 
	 	By:
	 	/s/ Samuel D. Isaly
	 
	 	 	 	 
	 
	 	 	 	Name: Samuel D. Isaly
	 
	 	 	 	Title: Managing Member, OrbiMed Advisors LLC
	 
	 	 	 	 
	 	 	          United Kingdom
	 	 	 
	 	 	     Jurisdiction of organization of entity

	 	 	 	 	 
	 
	 	Address:
	 	c/o OrbiMed Advisors LLC
	 
	 	 	 	767 Third Avenue, 30th Fl

New York, NY 10017

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $1,459,500
	 	 	600,000	 	 	 	540,000	 

[Signature Page To Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Kingsbrook Opportunities Master Fund LP	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Kingsbrook Opportunities GP LLC	 	 
	 

	 	Its:
	 	General Partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Adam J. Chill
	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Adam J. Chill	 	 
	 

	 	 	 	Title: Managing Member	 	 
	 
	 	 	 	 	 	 
	 	 	Cayman Islands
	 	 
	 	 	 	 	 
	 	 	Jurisdiction of organization of entity
	 	 

	 	 	 	 	 	 	 
	 

	 	Address:
	 	c/o Kingsbrook Partners LP
	 	 
	 

	 	 	 	590 Madison Avenue, 27th Floor	 	 
	 

	 	 	 	New York, NY 10022	 	 
	 

	 	 	 	Attn: Ari Storch/Adam Chill	 	 
	 
	 	 	 	 	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $1,000,001

	 	 	411,100	 	 	 	369,990	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 	 	 
	 	 	Capital Ventures International	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Martin Kobinger
	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Martin Kobinger	 	 
	 

	 	 	 	Title: Investment Manager	 	 
	 
	 	 	 	 	 	 
	 	 	Cayman Islands
	 	 
	 	 	 	 	 
	 	 	Jurisdiction of organization of entity
	 	 

	 	 	 	 	 	 	 
	 

	 	Address:
	 	c/o Heights Capital Management, Inc.
	 	 
	 

	 	 	 	101 California Street, Suite 3250	 	 
	 

	 	 	 	San Francisco, CA 94111	 	 
	 

	 	 	 	Attn: Sam Winer	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $1,048,491

	 	 	431,034	 	 	 	387,931	 

[Signature Page to Securities Purchase Agreement]

 

 

	 	 	 	 	 
	 

	 	/s/ Thomas B. King
	 	 
	 

	 	 	 	 
	 

	 	Thomas B. King	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	California	 	 
	 

	 	 	 	 
	 

	 	Jurisdiction of residence	 	 

	 	 	 	 	 	 	 
	 

	 	Address:
	 	c/o Alexza Pharmaceuticals, Inc.
	 	 
	 

	 	 	 	2091 Stierlin Court	 	 
	 

	 	 	 	Mountain View, CA 94043	 	 

Aggregate dollar amount of Common Shares and Warrant Shares committed to be purchased pursuant to
the terms of the Agreement:

	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	Warrant Shares
	Purchase Price $157,274

	 	 	64,655	 	 	 	58,190	 

[Signature Page to Securities Purchase Agreement]

 

 

Attachment A

T. Rowe Price Health Sciences Fund, Inc.

Common Shares — 210,700

Warrant Shares — 189,630

Purchase Price = $512,527.75

T. Rowe Price Health Sciences Portfolio, Inc. 

Common Shares — 2,300

Warrant Shares — 2,070

Purchase Price = $5,594.75

TD Mutual Funds — TD Health Sciences Fund

Common Shares — 12,400

Warrant Shares — 11,160

Purchase Price = $30,163.00

VALIC Company I — Health Sciences Fund

Common Shares — 14,500

Warrant Shares — 13,050

Purchase Price = $35,271.25

John Hancock Trust — Health Sciences Trust 

Common Shares — 15,700

Warrant Shares —14,130

Purchase Price = $38,190.25

T. Rowe Price New Horizons Fund, Inc.

Common Shares — 700,000

Warrant Shares — 630,000

Purchase Price = $1,702,750.00

City of New York Deferred Compensation Plan — NYC 457/401K Small Cap Account 

Common Shares — 25,600

Warrant Shares — 23,040

Purchase Price = $62,272.00

T. Rowe Price New Horizons Trust

Common Shares — 22,000

Warrant Shares —19,800

Purchase Price = $53,515.00

T. Rowe Price U.S. Equities Trust

Common Shares — 1,700

 

 

Warrant Shares —1,530

Purchase Price = $4,135.25

 

 

Exhibit A

FORM OF WARRANT

Provided Separately

 

 

Exhibit B

FORM OF OPINION OF COMPANY COUNSEL

 

 

October 5, 2009

To the Purchasers Listed on Schedule I

RE:      Alexza Pharmaceuticals, Inc.

Ladies and Gentlemen:

We have acted as counsel for Alexza Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
in connection with the issuance and sale of 8,107,013 shares of the Company’s Common Stock (the
“Shares”) and warrants to purchase an additional 7,296,312 shares of the Company’s Common Stock
(the “Warrants”) to the Purchasers under the Securities Purchase Agreement, dated as of September
29, 2009 (the “Purchase Agreement”). We are rendering this opinion pursuant to Section 5.4 of the
Purchase Agreement. Except as otherwise defined herein, capitalized terms used but not defined
herein have the respective meanings given to them in the Purchase Agreement.

In connection with this opinion, we have examined and relied upon the representations and
warranties as to factual matters contained in and made pursuant to the Purchase Agreement by the
various parties and originals, or copies certified to our satisfaction, of such records, documents,
certificates, opinions, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below.

As to certain factual matters, we have relied upon certificates of officers of the Company and have
not sought independently to verify such matters. Where we render an opinion “to our knowledge” or
concerning an item “known to us” or our opinion otherwise refers to our knowledge, it is based
solely upon (i) an inquiry of attorneys currently within this firm who have represented the Company
in this transaction, (ii) receipt of a certificate executed by an officer of the Company covering
such matters and (iii) such other investigation, if any, that we specifically set forth herein.

In rendering this opinion, we have assumed: the authenticity of all documents submitted to us as
originals; the conformity to originals of all documents submitted to us as copies; the accuracy,
completeness and authenticity of certificates of public officials; the due authorization, execution
and delivery of all documents (except the due authorization, execution and delivery by the Company
of the Purchase Agreement), where authorization, execution and delivery are prerequisites to the
effectiveness of such documents; and the genuineness and authenticity of all signatures on original
documents (except the signature on behalf of the Company on the Purchase Agreement). We have also
assumed: that all individuals executing and delivering documents had the legal capacity to so
execute and deliver; that the Purchase Agreement is an obligation binding upon the parties thereto
other than the Company; and that there are no extrinsic agreements or understandings among the
parties to the Purchase Agreement or to the Material Agreements (as defined below) that would
modify or interpret the terms of any such agreements or the respective rights or obligations of the
parties thereunder.

Our opinion is expressed only with respect to the federal laws of the United States of America, the
laws of the State of California for the purposes of paragraphs 4 and 5 below, the laws of the State
of New York and the General Corporation Law of the State of Delaware. We express no

B-1

 

opinion as to whether the laws of any particular jurisdiction apply, and no opinion to the extent
that the laws of any jurisdiction other than those identified above are applicable to the subject
matter hereof.

We express no opinion as to any provisions of the Purchase Agreement that: (a) relate to the
subject matter jurisdiction of any federal court of the United States of America or any federal
appellate court to adjudicate any controversy related to the Purchase Agreement, (b) contains a
waiver of an inconvenient forum, or (c) relates to advance waivers of claims, defenses, rights
granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of
limitations, trial by jury, or procedural rights.

We are not rendering any opinion as to any statute, rule, regulation, ordinance, decree or
decisional law relating to antitrust, banking, land use, environmental, pension, employee benefit,
tax, usury, laws governing the legality of investments for regulated entities, regulations T, U or
X of the Board of Governors of the Federal Reserve System or local law. Furthermore, we express no
opinion with respect to compliance with antifraud laws, rules or regulations relating to securities
or the offer and sale thereof; compliance with the Investment Company Act of 1940, as amended;
compliance with fiduciary duties by the Company’s Board of Directors or stockholders; compliance
with safe harbors for disinterested Board of Director or stockholder approvals; compliance with
state securities or blue sky laws except as specifically set forth in paragraph 5 below; or
compliance with laws that place limitations on corporate distributions.

With regard to our opinion in paragraph 1 below, we have relied solely upon a certificate of the
Secretary of State of the State of Delaware as of a recent date. We have made no further
investigation.

With regard to our opinion in paragraph 3 below, with respect to the due and valid authorization of
the Purchase Agreement, we have relied solely upon (i) a certificate of an officer of the Company,
(ii) a review of the certificate of incorporation and bylaws of the Company, (iii) a review of the
resolutions certified by an officer of the Company, and (iv) a review of the Delaware General
Corporation Law. We have made no further investigation.

With regard to our opinion in paragraph 4 below concerning material defaults under and any material
breaches of any agreement identified on Schedule II hereto, we have relied solely upon (i) a
certificate of an officer of the Company, (ii) a list supplied to us by the Company of material
agreements to which the Company is a party, or by which it is bound, a copy of which is attached
hereto as Schedule II (the “Material Agreements”) and (iii) an examination of the Material
Agreements in the form provided to us by the Company. We have made no further investigation.
Further, with regard to our opinion in paragraph 4 below concerning Material Agreements, we express
no opinion as to (i) financial covenants or similar provisions therein requiring financial
calculations or determinations to ascertain compliance, (ii) provisions therein relating to the
occurrence of a “material adverse event” or words of similar import or (iii) any statement or
writing that may constitute parol evidence bearing on interpretation or construction.

With regard to our opinion in paragraph 7 below, we express no opinion to the extent that,
notwithstanding its current reservation of shares of Common Stock, future issuances of securities
of the Company and/or antidilution adjustments to outstanding securities of the

B-2

 

Company may cause the Warrant Shares to exceed the number of shares of Common Stock that then
remain authorized but unissued.

With regard to our opinion in paragraph 8 concerning exemption from registration, our opinion is
expressed only with respect to the offer and sale of the Shares, the Warrants and the Warrant
Shares without regard to any offers or sales of securities occurring prior to or subsequent to the
date hereof.

On the basis of the foregoing, in reliance thereon and with the qualifications set forth herein, we
are of the opinion that:

	1.	 	The Company has been duly incorporated and is a validly existing corporation in good standing
under the laws of the State of Delaware.

	2.	 	The Company has the corporate power to perform its obligations under the Purchase Agreement.

	3.	 	The Purchase Agreement has been duly and validly authorized, executed and delivered by the
Company. The offer and sale of the Shares and the Warrants have been duly authorized by the
Company.

	4.	 	The issuance of the Shares and the Warrants pursuant to the Purchase Agreement and the
Warrant Shares pursuant to the Warrants (assuming the exercise of the Warrants on the date
hereof) will not (a) violate any provision of the Company’s certificate of incorporation or
by-laws, (b) violate any governmental statute, rule or regulation which in our experience is
typically applicable to transactions of the nature contemplated by the Purchase Agreement, (c)
violate any order, writ, judgment, injunction, decree, determination or award which has been
entered against the Company and of which we are aware or (d) constitute a material default
under or a material breach of any Material Agreement, in the case of clauses (c) and (d) to
the extent such default or breach would materially and adversely affect the Company.

	5.	 	All consents, approvals, authorizations or orders of, and filings, registrations and
qualifications with, any U.S. Federal or California regulatory authority or governmental body
required for the sale and issuance of the Shares and the Warrants have been made or obtained,
except (a) for the filing of a Form D pursuant to Securities and Exchange Commission
Regulation D and (b) for the filing of the notice to be filed under California Corporations
Code Section 25102.1(d).

	6.	 	The Purchase Agreement constitutes a valid and binding agreement of the Company, enforceable
against the Company in accordance with its terms.

	7.	 	The Shares and the Warrant Shares, when sold and issued in accordance with the terms of the
Purchase Agreement or the Warrants, as applicable, will be validly issued, fully paid and
non-assessable, and the issuance of the Shares and the Warrant Shares is not subject to
preemptive rights pursuant to the General Corporation Law of the State of Delaware, the
certificate of incorporation or by-laws of the Company or similar rights to subscribe pursuant
to any Material Agreement.

B-3

 

	8.	 	The offer and sale of the Shares, the Warrants and the Warrant Shares (assuming exercise of
the Warrants on the date hereof) are exempt from the registration requirements of the
Securities Act of 1933, as amended, subject to the timely filing of a Form D pursuant to
Securities and Exchange Commission Regulation D.

Our opinion in paragraph 6 above is specifically subject to the following limitations, exceptions,
qualifications and assumptions:

     A. The opinions expressed above are subject to, and may be limited by, applicable bankruptcy,
reorganization, insolvency, moratorium, fraudulent conveyance, debtor and creditor, and similar
laws which relate to or affect creditors’ rights generally. This opinion is also subject to, and
may be limited by, general principles of equity and the exercise of judicial discretion (regardless
of whether such validity or enforceability is considered in a proceeding in equity or at law),
including the possible unavailability of specific performance, injunctive relief or any other
equitable remedy and concepts of materiality, reasonableness, conscionability, good faith and fair
dealing.

     B. We express no opinion as to the effect of court decisions, invoking statutes or principles
of equity, which have held that certain covenants and provisions of agreements are unenforceable
where enforcement of such covenants or provisions under the circumstances would violate the
enforcing party’s implied covenant of good faith and fair dealing or would be limited by the
principles of course of dealing or course of performance.

     C. We express no opinion as to the effect of any federal or state law or equitable principle
which provides that a court may refuse to enforce, or may limit the application of, a contract or
any clause thereof that the courts find to be unconscionable at the time it was made or contrary to
public policy.

     D. We express no opinion as to the enforceability under certain circumstances of provisions
expressly or by implication waiving broadly or vaguely stated rights, unknown future rights
including without limitation rights to damages, or defenses to obligations or rights granted by
law, when such waivers are against public policy or prohibited by law.

     E. We express no opinion as to the enforceability under certain circumstances of provisions to
the effect that rights or remedies are not exclusive, that rights or remedies may be exercised
without notice, that every right or remedy is cumulative and may be exercised in addition to or
with any other right or remedy, that election of a particular remedy or remedies does not preclude
recourse to one or more remedies, or that failure to exercise or delay in exercising rights or
remedies will not operate as a waiver of any such right or remedy.

     F. We express no opinion as to the enforceability of any provision of an applicable agreement
requiring that waivers must be in writing; such provision may not be binding or enforceable if a
non-executory oral agreement has been created modifying any such provision or if an implied
agreement by trade practice or course of conduct has given rise to a waiver.

     G. We express no opinion as to the enforceability of the following rights and remedies which
may be limited by applicable law: (i) any provision which provides for a rate of interest which
exceeds that permissible under applicable law; (ii) any provision which purports to

B-4

 

affect the jurisdiction of a court (including provisions as to methods of service of process
and as to property which may be subject to such jurisdiction) or may be subject to the discretion
of a court (including provisions as to venue); (iii) any provision which purports to make available
remedies for violations, breaches or defaults that are determined by a court of competent
jurisdiction to be non-material or unreasonable; (iv) any provision which provides for a choice of
law or choice of forum; (v) any provision relating to contribution to or the indemnification or
exculpation of any party; and (vi) any provision that contains a waiver of the benefits of
statutory, regulatory, or constitutional rights, unless and to the extent the statute, regulation,
or constitution explicitly allows waiver, including without limitation, any provision which
purports to waive trial by jury.

     H. We express no opinion with respect to the following: (i) any document referenced in the
Purchase Agreement; and (ii) the enforceability of the Purchase Agreement by or against any person
or entity that is not a party thereto.

     I. We express no opinion as to the enforceability of any provision for penalties, liquidated
damages, acceleration of future amounts due (other than principal) without appropriate discount to
present value, late charges, prepayment charges, or increased interest rates upon default.

     J. We express no opinion as the enforceability of any provision stating that the provisions of
a contract are severable.

     K. We express no opinion as to the enforceability of any provision that would permit the other
party to require performance without requiring consideration of the impracticability or
impossibility of performance at the time of attempted enforcement due to unforeseen circumstances
not within the contemplation of the parties.

This opinion is limited to the matters expressly set forth herein, and no opinion, express or
implied, is given beyond the matters expressly stated. This opinion speaks only as to the laws and
facts in effect or existing as of the date hereof, and we have no obligation to update or
supplement this opinion to reflect any facts or circumstances that may hereafter come to our
attention or any changes in law that may hereafter occur.

This opinion is intended solely for your benefit and is not to be made available to or be relied
upon by any other person, firm, or entity without our prior written consent.

Sincerely,

Cooley Godward Kronish LLP

	 	 	 	 	 
	By:
	 	 	 	 
	 

	 	 

Brent D. Fassett
	 	 

B-5

 

Schedule I

List of Purchasers

B-6

 

Schedule II

List of Material Agreements

	1.	 	Lease between the Company and Brittania, LLC dated August 25, 2006.
	 
	2.	 	First Amendment to Lease between the Company and Britannia Hacienda VIII LLC dated May 4,
2007.
	 
	3.	 	Second Amendment to Lease between the Company and Britannia Hacienda VIII LLC dated August
28, 2007.
	 
	4.	 	2009-2010 Performance Based Incentive Program.
	 
	5.	 	Second Amended and Restated Investors’ Rights Agreement between the Company and certain
holders of Preferred Stock dated November 5, 2004.
	 
	6.	 	2005 Equity Incentive Plan.
	 
	7.	 	2005 Non-Employee Directors’ Stock Option Plan.
	 
	8.	 	2005 Employee Stock Purchase Plan.
	 
	9.	 	Development Agreement between the Company and Autoliv ASP, Inc. dated October 3, 2005.
	 
	10.	 	Manufacturing and Supply Agreement between the Company and Autoliv ASP dated November 2,
2007.
	 
	11.	 	Master Security Agreement between the Company and General Electric Capital Corporation dated
May 17, 2005, as amended on May 18, 2005.
	 
	12.	 	Promissory Note between the Company and General Electric Capital Corporation dated June 15,
2005.
	 
	13.	 	Promissory Note between the Company and General Electric Capital Corporation dated August 24,
2005.
	 
	14.	 	Warrant to Purchase shares of Series B Preferred Stock issued to Silicon Valley Bank dated
March 20, 2002.
	 
	15.	 	Warrant to Purchase shares of Series C Preferred Stock issued to Silicon Valley Bank dated
January 30, 2003, as amended on March 4, 2003.
	 
	16.	 	Warrant to Purchase shares of Series C Preferred Stock issued to Silicon Valley Bank dated
September 19, 2003.
	 
	17.	 	Warrant to Purchase shares of Series C Preferred Stock issued to Silicon Valley Bank dated
April 7, 2004.
	 
	18.	 	Stock and Warrant Purchase Agreement between the Company and Biomedical Investment Fund Pte
Ltd. dated March 26, 2008.

B-7

 

	19.	 	Warrant to Purchase shares of Common Stock issued to Biomedical Investment Fund Pte Ltd.
dated March 27, 2008.
	 
	20.	 	Common Stock Purchase Agreement between the Company and Azimuth Opportunity Ltd. dated March
31, 2009.
	 
	21.	 	Amended and Restated Purchase Option Agreement by and among the Company, Symphony Allegro
Holdings LLC and Symphony Allegro, Inc. dated June 15, 2009.
	 
	22.	 	Amended and Restated Registration Rights Agreement between the Company and Symphony Allegro
Holdings LLC dated June 15, 2009.
	 
	23.	 	Warrants to Purchase shares of Common Stock issued to the investors identified in the
Registration Statement on Form S-1 filed by the Company on September 9, 2009, dated August 26,
2009.
	 
	24.	 	Letter Agreement among the Company, Symphony Allegro Holdings LLC, Symphony Capital Partners,
L.P. and Symphony Strategic Partners, LLC dated August 26, 2009.

B-8

 

Exhibit C

ALEXZA PHARMACEUTICALS, INC.

PURCHASER QUESTIONNAIRE

     In connection with the preparation of the Registration Statement, please provide us with the
following information regarding the Purchaser.

A. General Information

     1. Please state your organization’s name exactly as it should appear in the Registration
Statement:                                                             

     2. Have you or your organization had any position, office or other material relationship
within the past three years with the Company or its affiliates other than as disclosed in the
Prospectus included in the Registration Statement?

 ̈ Yes        ̈ No

     If yes, please indicate the nature of any such relationships below:

 

 

B. Securities Holdings

     Please fill in all blanks in the following questions related to your beneficial ownership
of the Company’s capital stock. Generally, the term “beneficial ownership” refers to any
direct or indirect interest in the securities which entitles you to any of the rights or benefits
of ownership, even though you may not be the holder of record of the securities. For example,
securities held in “street name” over which you exercise voting or investment power would be
considered beneficially owned by you. Other examples of indirect ownership include ownership by a
partnership in which you are a partner or by an estate or trust of which you or any member of your
immediate family is a beneficiary. Ownership of securities held in the names of your spouse, minor
children or other relatives who live in the same household may be attributed to you.

     Please note: If you have any reason to believe that any interest in securities of the
Company which you may have, however remote, is a beneficial interest, please describe such
interest. For purposes of responding to this questionnaire, it is preferable to err on the side of
inclusion rather than exclusion. Where the SEC’s interpretation of beneficial ownership would
require disclosure of your interest or possible interest in certain securities of the Company, and
you believe that you do not actually possess the attributes of beneficial ownership, an appropriate
response is to disclose the interest and at the same time disclaim beneficial ownership of the
securities.

 

 

     1. As of September 29, 2009, I owned outright (including shares registered in my name
individually or jointly with others, shares held in the name of a bank, broker, nominee, depository
or in “street name” for my account), the following number of shares of the Company’s capital stock:
                    .

     2. In addition to the number of shares I own outright as indicated by my answer to question
B(1), as of September 29, 2009, I had or shared voting power or investment power, directly
or indirectly, through a contract, arrangement, understanding, relationship or otherwise, over the
following number of shares of the Company’s capital stock:                     .

     If the answer to this question B(2) was not “zero,” please complete the following: with whom
shared; and the nature of the relationship and any underlying voting trust agreement, investment
arrangement or the like:

Shared Voting Power:

	 	 	 	 	 
	Number of Shares	 	With Whom Shared	 	Nature of Relationship
	 	 	 	 	 

Shared Investment Power:

	 	 	 	 	 
	Number of Shares	 	With Whom Shared	 	Nature of Relationship
	 	 	 	 	 

     3. As of November 29, 2009, I will have the right to acquire ___shares of the
Company’s capital stock pursuant to outstanding stock options issued under the Company’s stock
option plans and ___shares pursuant to the exercise of outstanding warrants (none, indicated by
“0” above).

	 	 	 
	Options and Warrants
	Class	 	Number of Shares
	 	 	 

C-2.

 

     4. Please identify the natural person or persons who have voting and/or investment control
over the Company’s securities that you own, and state whether such person(s) disclaims beneficial
ownership of the securities. For example, if you are a general partnership, please identify
the general partners in the partnership.

 

 

 

 

 

 

C-3.

 

C. FINRA Questions

     1. Are you (i) a “member”1 of the Financial Industry Regulatory Authority
(“FINRA”), (ii) an “affiliate”2 of a member of FINRA, (iii) a “person associated with a
member” or an “associated person of a member”3 of FINRA or (iv) an immediate family
member4 of any of the foregoing persons? If yes, please identify the member and
describe such relationship (whether direct or indirect), and please respond to Question Number 2
below; if no, please proceed directly to Question Number 3.

Yes o      No o

Description:

 

			
	1	 	FINRA defines a “member” as any broker or dealer
admitted to membership in FINRA, or any officer or partner or branch manager of
such a member, or any person occupying a similar status or performing a similar
function for such a member.
	 
	2	 	The term “affiliate” means a person that directly,
or indirectly through one or more intermediaries, controls, or is controlled
by, or is in common control with, the person specified. Persons who have acted
or are acting on behalf of or for the benefit of a person include, but are not
necessarily limited to, directors, officers, employees, agents, consultants and
sales representatives. The following should apply for purposes of the
foregoing:

	 	(i)	 	a person should be presumed to control a Member if the person beneficially
owns 10 percent or more the outstanding voting securities of a Member which is
a corporation, or beneficially owns a partnership interest in 10 percent or
more of the distributable profits or losses of a Member which is a partnership;
	 
	 	(ii)	 	a Member should be presumed to control a person if the Member and Persons
Associated With a Member beneficially own 10 percent or more of the outstanding
voting securities of a person which is a corporation, or beneficially own a
partnership interest in 10 percent or more of the distributable profits or
losses of a person which is a partnership;
	 
	 	(iii)	 	a person should be presumed to be under common control with a Member if:

	 	(1)	 	the same person controls both the Member and another person by
beneficially owning 10 percent or more of the outstanding voting
securities of a Member or person which is a corporation, or by
beneficially owning a partnership interest in 10 percent or more of the
distributable profits or losses of a Member or person which is a
partnership; or
	 
	 	(2)	 	a person having the power to direct or cause the direction of the management
or policies of the Member or such person also has the power to direct or cause
the direction of the management or policies of the other entity in question.

 

			
	3	 	FINRA defines a “person associated with a member” or
an “associated person of a member” as being every sole proprietor, partner,
equity owner, officer, director or branch manager of any member, or any natural
person occupying a similar status or performing similar functions, or any
natural person engaged in the investment banking or securities business who
directly or indirectly controls or is controlled by such member (for example,
any employee), whether or not any such person is registered or exempt from
registration with FINRA.
	 
	4	 	Immediate family includes parents, mother-in-law,
father-in-law, husband or wife, brother or sister, brother-in-law or
sister-in-law, son-in-law or daughter-in-law, and children, or any other person
who is supported, directly or indirectly, to a material extent, by a person
associated with a member of FINRA or any other broker/dealer.

C-4.

 

     2. If you answered “yes” to Question Number 1, please furnish any information as to whether
any such member intends to participate in any capacity in the public offering, including the
details of such participation:

Description:

     3. Are you or have you been an “underwriter or related person”5 or a person
associated with an underwriter or related person, including, without limitation, with respect to
the proposed public offering? If yes, please identify the underwriter or related person and
describe such relationship (whether direct or indirect).

Yes o      No o

Description:

     4. If known, please describe in detail any underwriting compensations, arrangements or
dealings entered into during the previous twelve months, or proposed to be consummated in the next
twelve months, between (i) any underwriter or related person, member of the FINRA,
affiliate of a member of the FINRA, person associated with a member or associated person
of a member of the FINRA or any immediate family member thereof, on the one hand, and (ii)
the Company, or any director, officer or stockholder thereof, on the other hand, which provides for
the receipt of any item of value and/or the transfer of any warrants, options or other securities
from the Company to any such person (other than the information relating to the arrangements with
any investment firm or underwriting organization which may participate in the proposed public
offering).

Description:

     5. Have you purchased the securities in the ordinary course of business?

Yes o      No o

 

			
	5	 	The term “underwriter or related person” includes
underwriters, underwriters’ counsel, financial consultants and advisors,
finders, members of the selling or distribution group, and any and all other
persons associated with or related to any of such persons, including members of
the immediate family of such persons.

C-5.

 

The answers to the foregoing questions are correctly stated to the best of my information and
belief. I shall advise Brent D. Fassett at (720) 566-4099, the Company’s outside counsel, promptly
of any changes in the foregoing information prior to the effectiveness of the Registration
Statement.

	 	 	 	 	 
	 

	 	 

(Print name of Selling Security Holder)
	 	 
	 
	 	 	 	 
	 

	 	 

(Signature)
	 	 
	 
	 	 	 	 
	 

	 	By:  

(Name
and title of signatory, if stockholder is an entity)
	 	 
	 
	 	 	 	 
	 

	 	 

(Date)
	 	 

C-6.

 

Exhibit D

Form of Irrevocable Transfer Agent Instructions

As of                     , 200[_]

Mellon Investor Services, LLC

520 Pike Street, Suite 1220

Seattle, WA 98101

Attn: Lisa Porter

Ladies and Gentlemen:

      Reference is made to that certain Securities Purchase Agreement, dated as of September
29, 2009 (the “Agreement”), by and among Alexza Pharmaceuticals, Inc. (the “Company”), and the
purchasers named on the signature pages thereto (collectively, and including permitted transferees,
the “Holders”), pursuant to which the Company is issuing to the Holders shares of common stock (the
“Shares”) of the Company, par value $0.0001 per share (the “Common Stock”).

      This letter shall serve as our irrevocable authorization and direction to you (provided
that you are the transfer agent of the Company at such time and the conditions set forth in this
letter are satisfied), subject to any stop transfer instructions that we may issue to you from time
to time, if any, to issue certificates representing shares of Common Stock to a Holder from time to
time upon delivery to you of instructions by the Company as indicated in writing executed by a duly
authorized officer of the Company together with indication of receipt of the exercise price
therefor.

     You acknowledge and agree that so long as you have received (a) written confirmation from the
Company’s legal counsel that either (1) a registration statement covering resales of the Shares has
been declared effective by the Securities and Exchange Commission (the “Commission”) under the
Securities Act of 1933, as amended (the “Securities Act”), or (2) the Shares have been sold in
conformity with Rule 144 under the Securities Act (“Rule 144”) or are eligible for sale under Rule
144, without the requirement for the Company to be in compliance with the current public
information required under Rule 144 as to such securities and without volume or manner-of-sale
restrictions and (b) if applicable, a copy of such registration statement, then, unless otherwise
required by law, as soon as is reasonably practicable after your receipt of written authorization
from a duly authorized officer of the Company that the Common Stock may be issued, you shall issue
the certificates representing the Common Stock registered in the names of such Holders or
transferees, as the case may be, and such certificates shall not bear any legend restricting
transfer of the Shares thereby and should not be subject to any stop-transfer restriction;
provided, however, that if such Shares are not registered for resale under the Securities Act or
able to be sold under Rule 144 without the requirement for the Company to be in compliance with the
current public information required under Rule 144 as to such securities and without volume or
manner-of-sale restrictions, then the certificates for such Shares shall bear the following
restrictive legend:

     THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B)
AN AVAILABLE EXEMPTION

D-1.

 

\

FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF
COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR
(II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT (PROVIDED THAT THE
TRANSFEROR PROVIDES THE COMPANY WITH REASONABLE ASSURANCES (IN THE FORM
OF SELLER AND BROKER REPRESENTATION LETTERS) THAT THE SECURITIES MAY BE
SOLD PURSUANT TO SUCH RULE). NO REPRESENTATION IS MADE BY THE ISSUER AS
TO THE AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 UNDER THE
SECURITIES ACT FOR RESALES OF THESE SECURITIES.

     A form of written confirmation from the Company’s outside legal counsel that a registration
statement covering resales of the Shares has been declared effective by the Commission under the
Securities Act is attached hereto as Annex I.

      Please execute this letter in the space indicated to acknowledge your agreement to act
in accordance with these instructions.

	 	 	 	 	 	 	 
	 	 	Very truly yours,
	 
	 	 	 	 	 	 
	 	 	ALEXZA PHARMACEUTICALS, INC.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	 
 

	 	 
	 

	 	Name:
	 	 
 

	 	 
	 

	 	Title:
	 	 
 

	 	 

Acknowledged and Agreed:

MELLON INVESTOR SERVICES, LLC

	 	 	 	 	 
	By:

	 	 
 

	 	 
	Name:

	 	 
 

	 	 
	Title:

	 	 
 

	 	 

Date:                     

D-2.exv10w54

Exhibit 10.54

     THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.

ALEXZA PHARMACEUTICALS, INC.

WARRANT

dated as of October 5, 2009

     THIS CERTIFIES THAT, for value received, [                    ] or its successors or permitted
assigns (such Person and such successors and assigns each being the “Warrant Holder” with respect
to the Warrant held by it), at any time and from time to time on any Business Day on or prior to
5:00 p.m. (New York City time), on the Expiration Date (as herein defined), is entitled (a) to
subscribe for the purchase from Alexza Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), [                    ] Shares at a price per Share equal to the Exercise Price (as herein defined),
and (b) to the other rights set forth herein; provided that the number of Shares issuable
upon any exercise of this Warrant and the Exercise Price shall be adjusted and readjusted from time
to time in accordance with Section 5. By accepting delivery hereof, the Warrant Holder agrees to
be bound by the provisions hereof.

     This Warrant (the “Warrant”) is issued as part of a series of similar Warrants
(collectively, the “Warrants”) issued pursuant to that certain Securities Purchase
Agreement, dated as of September 29, 2009, by and among the Company and the other parties
identified therein (the “Purchase Agreement”).

     IN FURTHERANCE THEREOF, the Company irrevocably undertakes and agrees for the benefit of
Warrant Holder as follows:

     Section 1. Definitions and Construction.

     (a) Certain Definitions. As used herein (the following definitions being applicable
in both singular and plural forms):

     “Affiliate” means, with respect to any Person, any other Person that directly or
indirectly controls, is controlled by, or is under common control with such Person.

     “Appraised Value” means at any time the fair market value thereof determined in good
faith by the Board of Directors of the Company as of a date which is within ten (10) days of the
date as of which the determination is to be made, subject to the rights of the Requisite Holders
pursuant to Section 5(j).

     “Business Day” means any day except a Saturday, Sunday or other day on which
commercial banks in New York City are authorized by law to close.

     “Closing Price” means, for any trading day with respect to a Share, (a) the last
reported sale price on such day on the principal national securities exchange on which the Shares
are listed or admitted to trading or, if no such reported sale takes place on any such day, the
average of the closing bid and asked prices thereon, as reported in The Wall Street
Journal, or (b) if such Shares shall not be listed or admitted to trading on a national
securities exchange, the last reported sales price on the NASDAQ National Market System or, if no
such reported sale takes place on any such day, the average of the closing bid and asked prices
thereon, as reported in The Wall Street Journal, or (c) if such Shares shall not be quoted
on such National Market System nor listed or admitted to trading on a national securities exchange,
then the average of the closing bid and asked prices, as reported by The Wall Street
Journal for the over-the-

1.

 

counter market; provided that if clause (a), (b), or (c) applies and no price
is reported in The Wall Street Journal for any trading day, then the price reported in
The Wall Street Journal for the most recent prior trading day shall be deemed to be the
price reported for such trading day.

     “Commission” means the Securities and Exchange Commission or any other Federal agency
administering the Securities Act at the time.

     “Exchange Act” means the Securities Exchange Act of 1934, or any successor Federal
statute, and the rules and regulations of the Commission thereunder, all as the same shall be in
effect at the time.

     “Exercise Amount” means for any number of Warrant Shares as to which this Warrant is
being exercised the product of (i) such number of Warrant Shares times (ii) the Exercise
Price.

     “Exercise Price” means $2.77 per Warrant Share, as adjusted from time to time pursuant
to Section 5.

     “Expiration Date” means October 5, 2016.

     “Initial Holder” means [                    ].

     “Person” means an individual, a corporation, a partnership, an association, a trust or
any other entity or organization, including a government or political subdivision or an agency or
instrumentality thereof.

     “Requisite Holders” means at any time holders of Warrant Shares and Warrants
representing at least two-thirds of the Warrant Shares outstanding or issuable upon the exercise of
all the outstanding Warrants.

     “Securities Act” means the Securities Act of 1933, or any successor Federal statute,
and the rules and regulations of the Commission thereunder, all as the same shall be in effect at
the time.

     “Shares” means the Company’s currently authorized common stock, $0.0001 par value, and
stock of any other class or other consideration into which such currently authorized capital stock
may hereafter have been changed.

     “Warrant” means, as the context requires, this warrant and any successor warrant or
warrants issued upon a whole or partial transfer or assignment of any such Share purchase warrant
or of any such successor warrant.

     “Warrant Shares” means the number of Shares issued or issuable upon exercise of this
Warrant as set forth in the introduction hereto, as adjusted from time to time pursuant to
Section 5, or in the case of other Warrants, issuable upon exercise of those Warrants.

     (b) Accounting Terms and Determinations. Unless otherwise specified herein, all
accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be
made, and all financial statements required to be delivered hereunder shall be prepared, in
accordance with generally accepted accounting principles. When used herein, the term “financial
statements” shall include the notes and schedules thereto. References to fiscal periods are to
fiscal periods of the Company.

     (c) Computation of Time Periods. With respect to the computation of periods of time
from a specified date to a later specified date, the word “from” means “from and including” and the
words “to” and “until” each mean “to but excluding.” Periods of days shall be counted in calendar
days unless otherwise stated.

     (d) Construction. Unless the context requires otherwise, references to the plural
include the singular and to the singular include the plural, references to any gender include any
other gender, the part includes the whole, the term “including” is not limiting, and the term “or”
has, except where otherwise

2.

 

indicated, the inclusive meaning represented by the phrase “and/or.” The words “hereof,”
“herein,” “hereby,” “hereunder,” and similar terms in this Warrant refer to this Warrant as a whole
and not to any particular provision of this Warrant. Section, subsection, clause, exhibit and
schedule references are to this Warrant, unless otherwise specified. Any reference to this Warrant
includes any and all permitted alterations, amendments, changes, extensions, modifications,
renewals, or supplements thereto or thereof, as applicable.

     (e) Exhibits and Schedules. All of the exhibits and schedules attached hereto shall
be deemed incorporated herein by reference.

     (f) No Presumption Against Any Party. Neither this Warrant nor any uncertainty or
ambiguity herein or therein shall be construed or resolved using any presumption against any party
hereto or thereto, whether under any rule of construction or otherwise. On the contrary, this
Warrant has been reviewed by each of the parties and their counsel and, in the case of any
ambiguity or uncertainty, shall be construed and interpreted according to the ordinary meaning of
the words used so as to fairly accomplish the purposes and intentions of all parties hereto.

     Section 2. Exercise of Warrant.

     (a) Exercise and Payment. The Warrant Holder may exercise this Warrant in whole or in
part, at any time or from time to time on any Business Day on or prior to the Expiration Date, by
delivering to the Company a duly executed notice (a “Notice of Exercise”) in the form of
Exhibit A and by payment to the Company of the Exercise Price per Warrant Share, at the
election of the Warrant Holder, either (a) by wire transfer of immediately available funds to the
account of the Company in an amount equal to the Exercise Amount, (b) by receiving from the Company
the number of Warrant Shares equal to (i) the number of Warrant Shares as to which this Warrant is
being exercised minus (ii) the number of Warrant Shares having a value, based on the Closing Price
on the trading day immediately prior to the date of such exercise (or if there is no such Closing
Price, then based on the Appraised Value as of such day), equal to the Exercise Amount, or (c) any
combination of the foregoing. The Company acknowledges that the provisions of clause (b) are
intended, in part, to ensure that a full or partial exchange of this Warrant pursuant to such
clause (b) will qualify as a conversion, within the meaning of paragraph (d)(3)(ii) of Rule 144
under the Securities Act. At the request of any Holder, the Company will accept reasonable
modifications to the exchange procedures provided for in this Section in order to accomplish such
intent. For all purposes of this Warrant (other than this Section 2(a)), any reference herein to
the exercise of this Warrant shall be deemed to include a reference to the exchange of this Warrant
into Shares in accordance with the terms of clause (b).

     (b) Effectiveness and Delivery. The Company shall confirm receipt of any Notice of
Exercise delivered pursuant to Section 2(a) within one Business Day of the receipt thereof. As
soon as practicable but not later than three Business Days after the Company shall have received
such Notice of Exercise and payment, the Company shall execute and deliver or cause to be executed
and delivered, in accordance with such Notice of Exercise, a certificate or certificates
representing the number of Shares specified in such Notice of Exercise, issued in the name of the
Warrant Holder or in such other name or names of any Person or Persons designated in such Notice of
Exercise. Without prejudice to the holding periods determined under Rule 144 under the Securities
Act, this Warrant shall be deemed to have been exercised and such Share certificate or certificates
shall be deemed to have been issued, and the Warrant Holder or other Person or Persons designated
in such Notice of Exercise shall be deemed for all purposes to have become a holder of record of
Shares, all as of the date that such Notice of Exercise and payment shall have been received by the
Company.

3.

 

     (c) Surrender of Warrant. The Warrant Holder shall surrender this Warrant to the
Company within five Business Days after it delivers the Notice of Exercise, and in the event of a
partial exercise of the Warrant, the Company shall execute and deliver to the Warrant Holder, at
the time the Company delivers the Share certificate or certificates issued pursuant to such Notice
of Exercise, a new Warrant for the unexercised portion of the Warrant, but in all other respects
identical to this Warrant.

     (d) Legend. Subject to the provisions of the Purchase Agreement, each certificate for
Warrant Shares issued upon exercise of this Warrant, unless at the time of exercise such Warrant
Shares are registered under the Securities Act, shall bear the following legend:

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION
FROM SUCH REGISTRATION IS AVAILABLE.

     Any certificate for Warrant Shares issued at any time in exchange or substitution for any
certificate bearing such legend (unless at that time such Warrant Shares are registered under the
Securities Act or otherwise may be issued without legends in accordance with the terms of the
Purchase Agreement or under Rule 144 under the Securities Act) shall also bear such legend unless,
in the written opinion of counsel selected by the holder of such certificate (who may be an
employee of such holder), which counsel and opinion shall be reasonably acceptable to the Company,
the Warrant Shares represented thereby need no longer be subject to restrictions on resale under
the Securities Act.

     (e) Fractional Shares. The Company shall not be required to issue fractions of Shares
upon an exercise of the Warrant. If any fraction of a Share would, but for this restriction, be
issuable upon an exercise of the Warrant, in lieu of delivering such fractional Share, the Company
shall pay to the Warrant Holder, in cash, an amount equal to the same fraction times the Closing
Price on the trading day immediately prior to the date of such exercise (or if there is no such
Closing Price, then based on the Appraised Value as of such day).

     (f) Expenses and Taxes. The Company shall pay all expenses, taxes and owner charges
payable in connection with the preparation, issuance and delivery of certificates for the Warrant
Shares and any new Warrants, except that if the certificates for the Warrant Shares or the new
Warrants are to be registered in a name or names other than the name of the Warrant Holder, funds
sufficient to pay all transfer taxes payable as a result of such transfer shall be paid by the
Warrant Holder at the time of its delivery of the Notice of Exercise or promptly upon receipt of a
written request by the Company for payment.

     (g) Automatic Cashless Exercise. To the extent that the Closing Price on the trading
day immediately prior to the Expiration Date (or if there is no such Closing Price, then based on
the Appraised Value as of such day) is greater than the Exercise Price and there has not been an
exercise by the Warrant Holder pursuant to Section 2(a) hereof, any portion of the Warrant that
remains unexercised shall be exercised automatically in whole (not in part), upon the Expiration
Date. Payment by the Warrant Holder upon such automatic exercise shall be in the form of the
Warrant Holder receiving from the Company the number of Warrant Shares equal to (i) the number of
Warrant Shares as to which this Warrant is being automatically exercised minus (ii) the number of
Warrant Shares having a value, based on the Closing Price on the trading day immediately prior to
the date of such automatic exercise (or if there is no such Closing Price, then based on the
Appraised Value as of such day), equal to the Exercise Amount.

4.

 

     Section 3. Investment Representation. By accepting the Warrant, the Warrant Holder
represents that it is acquiring the Warrant for its own account and not with the view to any sale
or distribution, that the Warrant Holder will not offer, sell or otherwise dispose of the Warrant
or the Warrant Shares except under circumstances as will not result in a violation of applicable
securities laws, and that the Warrant Holder is an “accredited investor” as that term is defined in
Rule 501 under the Securities Act.

     Section 4. Validity of Warrant and Issuance of Shares.

     (a) The Company represents and warrants that this Warrant has been duly authorized, is validly
issued, and constitutes the valid and binding obligation of the Company and is enforceable against
the Company in accordance with its terms.

     (b) The Company further represents and warrants that on the date hereof it is duly authorized
and reserved, and the Company hereby agrees that it will at all times until the Expiration Date
have duly authorized and reserved, such number of Shares as will be sufficient to permit the
exercise in full of the Warrant, and that all such Shares are and will be duly authorized and, when
issued upon exercise of the Warrant, will be validly issued, fully paid and non-assessable, and
free and clear of all security interests, claims, liens, equities and other encumbrances.

     Section 5. Adjustment Provisions. The Exercise Price in effect at any time, and the
number of Warrant Shares that may be purchased upon any exercise of the Warrant, shall be subject
to change or adjustment as follows:

     (a) Share Reorganization. If the Company shall subdivide its outstanding Shares into
a greater number of Shares, by way of a stock split, stock dividend or otherwise, or consolidate
its outstanding Shares into a smaller number of Shares (any such event being herein called a
“Share Reorganization”), then (i) the Exercise Price shall be adjusted, effective
immediately after the effective date of such Share Reorganization, to a price determined by
multiplying the Exercise Price in effect immediately prior to such effective date by a fraction,
the numerator of which shall be the number of Shares outstanding on such effective date before
giving effect to such Share Reorganization and the denominator of which shall be the number of
Shares outstanding after giving effect to such Share Reorganization, and (ii) the number of Shares
subject to purchase upon exercise of this Warrant shall be adjusted, effective at such time, to a
number determined by multiplying the number of Shares subject to purchase immediately before such
Share Reorganization by a fraction, the numerator of which shall be the number of Shares
outstanding after giving effect to such Share Reorganization and the denominator of which shall be
the number of Shares outstanding immediately before giving effect to such Share Reorganization.

     (b) Special Distributions. If the Company shall issue or distribute to any holder or
holders of Shares evidences of indebtedness, any other securities of the Company or any cash,
property or other assets (excluding a Share Reorganization), whether or not accompanied by a
purchase, redemption or other acquisition of Shares (any such nonexcluded event being herein called
a “Special Distribution”), then the Warrant Holder shall be entitled to a pro-rata share of
such Special Distribution as though the Warrant Holder had fully exercised this Warrant immediately
prior to the record date for such Special Distribution, and the Company shall pay or distribute
such pro-rata share to Warrant Holder when paid or distributed to the holders of the Shares. A
reclassification of the Shares (other than a change in par value, or from par value to no par value
or from no par value to par value) into shares of any other class of stock shall be deemed to be a
distribution by the Company to the holders of its Shares of such class of stock and, if the
outstanding Shares shall be changed into a larger or smaller number of Shares as part of such
reclassification, a Share Reorganization.

5.

 

     (c) Capital Reorganization. Without limiting any of the other provisions hereof, if
any (i) capital reorganization; (ii) reclassification of the capital stock of the Company; (iii)
merger, consolidation or reorganization or other similar transaction or series of related
transactions which results in the voting securities of the Company outstanding immediately prior
thereto representing immediately thereafter (either by remaining outstanding or by being converted
into voting securities of the surviving or acquiring entity) less than 50% of the combined voting
power of the voting securities of or economic interests in the Company or such surviving or
acquiring entity outstanding immediately after such merger, consolidation or reorganization; (iv)
sale, lease, license, transfer, conveyance or other disposition of all or substantially all of the
assets of the Company; (v) sale of shares of capital stock of the Company, in a single transaction
or series of related transactions, representing at least 50% of the voting power of the voting
securities of or economic interests in the Company; or (vi) the acquisition by any “person”
(together with his, her or its Affiliates) or “group” (within the meaning of Section 13(d) or 14(d)
of the Exchange Act) acquires, directly or indirectly, the beneficial ownership (as such term is
defined in Rule 13d-3 promulgated under the Exchange Act) of outstanding shares of capital stock
and/or other equity securities of the Company, in a single transaction or series of related
transactions (including, without limitation, one or more tender offers or exchange offers),
representing at least 50% of the voting power of or economic interests in the then outstanding
shares of capital stock of the corporation (each of (i)-(vi) above a “Corporate Reorganization”)
shall be effected, then the Company shall use its commercially reasonable efforts to ensure that
lawful and adequate provision shall be made whereby each Warrant Holder shall thereafter continue
to have the right to purchase and receive upon the basis and upon the terms and conditions herein
specified and in lieu of the Warrant Shares issuable upon exercise of the Warrants held by such
Warrant Holder, shares of stock in the surviving or acquiring entity (“Acquirer”), as the
case may be, such that the aggregate value of the Warrant Holder’s warrants to purchase such number
of shares, where the value of each new warrant to purchase one share in the Acquirer is determined
in accordance with the Black-Scholes Option Pricing formula set forth in Appendix (A) hereto, is
equivalent to the aggregate value of the Warrants held by such Warrant Holder, where the value of
each Warrant to purchase one share in the Company is determined in accordance with the
Black-Scholes Option Pricing formula set forth Appendix (B) hereto. Furthermore, the new warrants
to purchase shares in the Acquirer referred to herein shall have the same expiration date as the
Warrants, and shall have a strike price, KAcq, that is calculated in accordance with
Appendix (A) hereto. For the avoidance of doubt, if the surviving or acquiring entity, as the case
may be, is a member of a consolidated group for financial reporting purposes, the “Acquirer” shall
be deemed to be the parent of such consolidated group for purposes of
this Section 5(c) and
Appendix (A) hereto.

Moreover, appropriate provision shall be made with respect to the rights and interests of each
Warrant Holder to the end that the provisions hereof (including, without limitation, provision for
adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be
practicable in relation to any shares of stock thereafter deliverable upon the exercise thereof.
The Company shall not effect any such Corporate Reorganization unless prior to or simultaneously
with the consummation thereof the successor corporation resulting from such consolidation or
merger, or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or entity shall assume by written instrument, reasonably deemed by the Board of
Directors of the Company and the Requisite Holders to be satisfactory in form and substance, the
obligation to deliver to the holder of the Warrants, at the last address of such holder appearing
on the books of the Company, such shares of stock, as, in accordance with the foregoing provisions,
such holder may be entitled to purchase, and the other obligations under these Warrants. The
provisions of this Section 5(c) shall similarly apply to successive Corporate Reorganizations. If
the Company, in spite of using its commercially reasonable efforts, is unable to cause these
Warrants to continue in full force and effect until the Expiration Date in connection with any
Corporate Reorganization, then the Company shall pay the Warrant Holders an amount per Warrant to
purchase one share in the Company that is calculated in accordance with the Black-Scholes Option
Pricing formula set forth in Appendix (B) hereto. Such payment shall be made in cash in the event
that the Corporate

6.

 

Reorganization results in the shareholders of the Company receiving cash from the Acquirer at the
closing of the transaction, and shall be made in shares of the Company (with the value of each
share in the Company is determined according to SCorp in Appendix (B) hereto) in the
event that the Corporate Reorganization results in the shareholders of the Company receiving shares
in the Acquirer or other entity at the closing of the transaction. In the event that the
shareholders of the Company receive both cash and shares at the closing of the transaction, such
payment to the Warrant Holders shall be also be made in both cash and shares in the same proportion
as the consideration received by the shareholders.

     (d) Adjustment Rules.

          (i) Any adjustments pursuant to this Section 5 shall be made successively whenever any event
referred to herein shall occur, except that, notwithstanding any other provision of this Section 5,
no adjustment shall be made to the number of Warrant Shares to be delivered to the Warrant Holder
(or to the Exercise Price) if such adjustment represents less than 1% of the number of Warrant
Shares previously required to be so delivered, but any lesser adjustment shall be carried forward
and shall be made at the time and together with the next subsequent adjustment which together with
any adjustments so carried forward shall amount to 1% or more of the number of Warrant Shares to be
so delivered.

          (ii) No adjustments shall be made pursuant to this Section 5 in respect of the issuance of
Warrant Shares upon exercise of the Warrant;

          (iii) If the Company shall take a record of the holders of its Shares for any purpose
referred to in this Section 5, then (x) such record date shall be deemed to be the date of the
issuance, sale, distribution or grant in question and (y) if the Company shall legally abandon such
action prior to effecting such action, no adjustment shall be made pursuant to this Section 5 in
respect of such action.

          (iv) In computing adjustments under this Section 5, (A) fractional interests in Shares shall
be taken into account to the nearest one-thousandth of a Share, and (B) calculations of the
Exercise Price shall be carried to the nearest one-thousandth of one cent.

     (e) Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to
the taking of any action which would require an adjustment pursuant to this Section 5, the
Company shall take any action which may be necessary, including obtaining regulatory approvals or
exemptions, in order that the Company may thereafter validly and legally issue as fully paid and
nonassessable all Shares which the Warrant Holder is entitled to receive upon exercise of the
Warrant.

     (f) Notice of Adjustment. Not less than 20 days prior to the record date or effective
date, as the case may be, of any action which requires or might require an adjustment or
readjustment pursuant to this Section 5, the Company shall give notice to the Warrant
Holder of such event, describing such event in reasonable detail and specifying the record date or
effective date, as the case may be, and, if determinable, the required adjustment and computation
thereof. If the required adjustment is not determinable as the time of such notice, the Company
shall give notice to the Warrant Holder of such adjustment and computation as soon as reasonably
practicable after such adjustment becomes determinable. In connection with any such adjustment or
readjustment, at its sole cost and expense, the Company will also cause independent certified
public accountants of recognized national standing (which may be the regular auditors of the
Company) selected by the Company to verify its computations and confirm that such computations were
made in accordance with this Section 5 and, in connection with the preparation of the Company’s
quarterly financial statements prepare a report setting forth such adjustment or readjustment and
showing in reasonable detail the method of calculation thereof and the facts upon which such
adjustment or readjustment is based, including a statement of (i) the number of Shares outstanding
or deemed to be outstanding, and (ii) the Exercise Price in effect immediately prior to such

7.

 

issue or sale and as adjusted and readjusted (if required by this Section 5) on account
thereof. The Company will forthwith mail a copy of each such report to the Warrant Holder and
will, upon the written request at any time of the Warrant Holder, furnish to such holder a like
report setting forth the Exercise Price at the time in effect and showing in reasonable detail how
it was calculated. The Company will also keep copies of all such reports at its office and will
cause the same to be available for inspection at such office during normal business hours by the
Warrant Holder or any prospective purchaser of this Warrant designated by the Warrant Holder.

     (g) Disputes. Any dispute which arises between the Warrant Holder and the Company
with respect to the calculation of the adjusted Exercise Price or Warrant Shares issuable upon
exercise shall be determined by the independent auditors of the Company in accordance with the
terms of this Warrant, and such determination shall be binding upon the Company and the holders of
the Warrants and the Warrant Shares if made in good faith and without manifest error.

     (h) Other Actions Affecting Shares.

          (i) Equitable Equivalent. In case any event shall occur as to which the provisions of
this Section 5 set forth above hereof are not strictly applicable but the failure to make any
adjustment would not, or if the application of the provisions of this Section 5 otherwise would
not, in the opinion of the Warrant Holder, fairly protect the purchase rights represented by this
Warrant in accordance with the essential intent and principles of this Section 5, then, in each
such case, at the request of the Warrant Holder, the Company shall appoint a firm of independent
investment bankers of recognized national standing (which shall be completely independent of the
Company and shall be satisfactory to the holder or the Requisite Holders), which shall give their
opinion upon the adjustment, if any, on a basis consistent with the essential intent and principles
established in this Section 5, necessary to preserve the purchase rights of such Warrant Holder
represented by this Warrant. Upon receipt of such opinion, the Company will promptly mail a copy
thereof to the holder of this Warrant and shall make the adjustments described therein.

          (ii) No Avoidance. The Company shall not, by amendment of its certificate of
incorporation or by-laws or through any consolidation, merger, reorganization, transfer of assets,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the holder of this Warrant against
dilution or other impairment as if the holder was a shareholder of the Company entitled to the
benefit of fiduciary duties afforded to shareholders under Delaware law.

     (i) Adjustment of Par Value. If for any reason (including the operation of the
adjustment provisions set forth in this Warrant), the Exercise Price on any date of exercise of
this Warrant shall not be lawful and adequate consideration for the issuance of the relevant
Warrant Shares, then the Company shall take such steps as are necessary (including the amendment of
its certificate of incorporation so as to reduce the par value of the Shares) to cause such
Exercise Price to be adequate and lawful consideration on the date the payment thereof is due, but
if the Company shall fail to take such steps, then the Company acknowledges that the Warrant Holder
shall have been damaged by the Company in an amount equal to an amount, which, when added to the
total Exercise Price for the relevant Warrant Shares, would equal lawful and adequate consideration
for the issuance of such Warrant Shares, and the Company irrevocably agrees that if the Warrant
Holder shall then forgive the right to recover such damages from the Company, such forgiveness
shall constitute, and Company shall accept such forgiveness as, additional lawful consideration for
the issuance of the relevant Warrant Shares.

8.

 

     (j) Appraisal.

          (i) If the Requisite Holders shall, for any reason whatsoever, disagree with the Company’s
determination of the Appraised Value of a Share, then such holders shall by notice to the Company
(an “Appraisal Notice”) given within sixty (60) days after the Company notifies the holders
of such determination, elect to dispute such determination, and such dispute shall be resolved as
set forth in clause (ii) of this Section.

          (ii) The Company shall within ten (10) days after an Appraisal Notice shall have been given,
engage an independent investment bank of national repute (the “Appraiser”) selected by the
Requisite Holders and retained pursuant to an engagement letter between the Company and the
Appraiser with respect to such valuation in form and substance reasonably acceptable to Requisite
Holders, to make an independent determination of the Appraised Value of a Share; such value shall
be determined without deduction for (a) liquidity considerations, (b) minority shareholder status,
or (c) any liquidation or other preference or any right of redemption in favor of any other equity
securities of the Company. The costs of engagement of such investment bank for any such
determination of Appraised Value shall be paid by the Company.

     Section 6. Registration Rights and Extension of Expiration Date. The Warrant Holder
is entitled to the benefit of certain registration rights with respect to the Warrant Shares as
provided in the Purchase Agreement, and any subsequent holder hereof shall be entitled to such
rights to the extent provided in the Purchase Agreement.

     Section 7. Transfer of Warrant. The Warrant Holder upon transfer of the Warrant must
deliver to the Company a duly executed Warrant Assignment in the form of Exhibit B and upon
surrender of this Warrant to the Company, the Company shall execute and deliver a new Warrant with
appropriate changes to reflect such Assignment, in the name or names of the assignee or assignees
specified in the Warrant Assignment or other instrument of assignment and, if the Warrant Holder’s
entire interest is not being transferred or assigned, in the name of the Warrant Holder, and upon
the Company’s execution and delivery of such new Warrant, this Warrant shall promptly be cancelled;
and provided that any assignee shall have all of the rights of an Initial Holder hereunder.
The Company shall pay any transfer tax imposed in connection with such assignment (if any). Any
transfer or exchange of this Warrant shall be without charge to the Warrant Holder (except as
provided above with respect to transfer taxes, if any) and any new Warrant issued shall be dated
the date hereof.

     Section 8. Assistance in Disposition of Warrant or Warrant Shares. Notwithstanding
any other provision herein, in the event that it becomes unlawful for the Warrant Holder to
continue to hold the Warrant, in whole or in part, or some or all of the Shares held by it, or
restrictions are imposed on any the Warrant Holder by any statute, regulation or governmental
authority which, in the judgment of the Warrant Holder, make it unduly burdensome to continue to
hold the Warrant or such Shares, the Warrant Holder may sell or otherwise dispose of the Warrant
(subject to the restrictions on transfer provided in Section 7) or its Shares, and the Company
agrees to provide reasonable assistance to the Warrant Holder in disposing of the Warrant and such
Shares in a prompt and orderly manner and, at the request of the Warrant Holder, to provide (and
authorize the Warrant Holder to provide) financial and other information concerning the Company to
any prospective purchaser of the Warrant or Shares owned by the Warrant Holder.

     Section 9 Identity of Transfer Agent. The Transfer Agent for the Shares is Mellon
Investor Services LLC. Upon the appointment of any subsequent transfer agent for the Shares, the
Company will mail to the Warrant Holder a statement setting forth the name and address of such
transfer agent.

9.

 

     Section 10. Covenants. The Company agrees that:

     (a) Information. So long as this Warrant remains outstanding or any Initial Holder
holds any Warrant Shares, the Company will deliver to the Warrant Holder (or Initial Holder) upon
the request of such Warrant Holder (or Initial Holder):

          (i) as soon as available and in any event within 120 days after the end of each fiscal year,
an audited consolidated balance sheet of the Company and its consolidated subsidiaries as of the
end of such fiscal year and the related consolidated statements of income, of cash flows, and of
changes in shareholders’ equity for such fiscal year, prepared in conformity with generally
accepted accounting principles in the United States applied on a consistent basis, except as
otherwise noted therein, and setting forth in each case in comparative form the figures for the
previous fiscal year, all in reasonable detail and reported on without qualification by public
accountants of nationally recognized standing;

          (ii) as soon as available but not later than 45 days after the end of each fiscal quarter, a
consolidated balance sheet of the Company as of the end of such fiscal quarter, and the related
consolidated statements of income, cash flows, and changes in shareholders’ equity for such fiscal
quarter and for the portion of the fiscal year ended at the end of such fiscal quarter, prepared in
conformity with generally accepted accounting principles in the United States applied on a
consistent basis, except for normal, recurring adjustments or to the extent that such financial
statements do not include footnotes or as otherwise noted therein, and setting forth, in each case,
in comparative form the figures for the corresponding fiscal quarter and the corresponding portion
of the previous fiscal year;

          (iii) promptly upon the filing thereof, copies of all registration statements (other than the
exhibits thereto and any registration statements on Form S-8 or its equivalent) and to the extent
the Company is required by law or pursuant to the terms of any outstanding indebtedness of the
Company to prepare such reports, any annual reports, quarterly reports and other periodic reports
pursuant to Section 13 or 15(d) of the Exchange Act actually prepared by the Company as soon as
available; and

          (iv) promptly, upon the issuance thereof, all statements and notices sent to the Company’s
shareholders.

     (b) Maintenance of Business. The Company (i) will, and will cause each of its
subsidiaries to, continue, to engage in the business the Company and its subsidiaries are engaged
in as of the date hereof and business activities substantially related thereto, (ii) will not, and
will not permit any of its subsidiaries to, expand into any other lines of business except those
lines of business in which they are engaged in as of the date hereof, and as substantially related
thereto, (iii) will preserve, renew, and keep in full force and effect, and will, and will cause
each of its subsidiaries to, preserve, renew, and keep in full force and effect, its existence as a
limited liability company and all material rights, privileges, and franchises necessary or
desirable in the customary conduct of business, and (iv) will not, and will not permit any of its
subsidiaries to, consolidate with or merge with or into any other Person or take any action in
furtherance thereof.

     (c) Securities Filings; Rules 144 & 144A. The Company will (i) file any reports
required to be filed by it under the Securities Act, the Exchange Act or the rules and regulations
adopted by the Commission thereunder, (ii) use its commercially reasonable efforts to cooperate
with the Warrant Holder and each holder of Warrant Shares in supplying such information concerning
the Company as may be necessary for the Warrant Holder or holder of Warrant Shares to complete and
file any information reporting forms currently or hereafter required by the Commission as a
condition to the availability of an exemption from the Securities Act for the sale of any Warrants
or Warrant Shares, (iii) take such further action as the Warrant Holder may reasonably request to
the extent required from time to time to enable

10.

 

the Warrant Holder to sell Warrant Shares without registration under the Securities Act within
the limitation of the exemptions provided by Rule 144 or 144A under the Securities Act, as such
Rules may be amended from time to time, or any similar rule or regulation hereafter adopted by the
Commission, and (iv) upon the request of the Warrant Holder, deliver to the Warrant Holder a
written statement as to whether it has complied with such reporting requirements; provided
that this subsection (c) shall not require the Company to make any filing under the
Securities Act or Exchange Act which the Company is not otherwise obligated to make.

     (d) Obtaining of Governmental Approvals and Stock Exchange Listings. The Company
will, at its own expense, (i) obtain and keep effective any and all permits, consents and approvals
of governmental agencies and authorities which may from time to time be required of the Company in
order to satisfy its obligations hereunder, and (ii) take all action which may be necessary so that
the Warrant Shares, immediately upon their issuance upon the exercise of the Warrants, will be
listed on each securities exchange, if any, on which the Shares are then listed.

     (e) Inspection and Access. So long as this Warrant remains outstanding or any Holder
holds any Warrant Shares, the Company shall permit any authorized representatives designated by the
Warrant Holder (or Initial Holder) to visit and inspect any of the properties of the Company and
its subsidiaries, including its and their books of account, and to discuss its and their affairs,
finances and accounts with its and their officers, all at such times as the Warrant Holder (or
Initial Holder) may request.

     (f) Structural Dilution. So long as this Warrant remains outstanding, the Company
shall not permit any of its subsidiaries to issue, sell, distribute or otherwise grant in any
manner (including by assumption) any rights to subscribe for or to purchase, or any warrants or
options for the purchase of any equity securities of such subsidiary or any securities convertible
into or exchangeable for such equity securities (or any rights to subscribe for or to purchase, or
any warrants or options for the purchase of any such convertible or exchangeable securities),
whether or not immediately exercisable or exercisable prior to the Expiration Date or thereafter.

     (g) Notices Of Corporate Action. In the event of:

          (i) any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any distribution, or any
right to subscribe for, purchase or otherwise acquire any Shares or any other securities or
property, or to receive any other right, or

          (ii) any capital reorganization of the Company, any reclassification or recapitalization of
the capital stock of the Company, any consolidation or merger involving the Company and any other
Person or any transfer of all or substantially all the assets of the Company to any other Person,
or any Corporate Reorganization, or

          (iii) any voluntary or involuntary dissolution, liquidation or winding-up of the Company,

     the Company will mail to the Warrant Holder a notice specifying (i) the date or expected date
on which any such record is to be taken for the purpose of such dividend, distribution or right,
and the amount and character of such dividend, distribution or right, (ii) the date or expected
date on which any such reorganization, reclassification, recapitalization, consolidation, merger,
transfer, dissolution, liquidation or winding-up is to take place, (iii) the time, if any such time
is to be fixed, as of which the holders of record of Shares (or other securities under Section
5(c)) shall be entitled to exchange their Shares (or other securities under Section 5(c)) for the
securities or other property deliverable upon such

11.

 

reorganization, reclassification, recapitalization, consolidation, merger, transfer,
dissolution, liquidation or winding-up and a description in reasonable detail of the transaction
and (iv) the date of such issuance, together with a description of the security so issued and the
consideration received by the Company therefor. Such notice shall be mailed at least forty-five
(45) days prior to the date therein specified.

     Section 11. Lost, Mutilated or Missing Warrants. Upon receipt by the Company of
evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of any
Warrant, and, in the case of loss, theft or destruction, upon receipt of indemnification
satisfactory to the Company (in the case of an Initial Holder its unsecured, unbonded agreement of
indemnity or affidavit of loss shall be sufficient) or, in the case of mutilation, upon surrender
and cancellation of the mutilated Warrant, the Company shall execute and deliver a new Warrant of
like tenor and representing the right to purchase the same aggregate number of Warrant Shares.

     Section 12. Limitation on Exercise. Notwithstanding anything to the contrary contained
herein, the number of Warrant Shares that may be acquired by the Warrant Holder upon any exercise
of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure
that, following such exercise (or other issuance), the total number of Shares then beneficially
owned by the Warrant Holder  and any other Persons whose beneficial ownership of
Shares would be aggregated with the Warrant Holder’s for purposes of Section 13(d) of the Exchange
Act, does not exceed 4.999% of the total number of then issued and outstanding Shares (including
for such purpose the Shares issuable upon such exercise). For such purposes, beneficial ownership
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder, it being acknowledged by the Warrant Holder that the Company
is not representing to such Warrant Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and such Warrant Holder is solely responsible for any schedules required
to be filed in accordance therewith. To the extent that the limitation contained in this Section
12 applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by such Warrant Holder) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Warrant Holder, and the submission of a Notice of Exercise shall
be deemed to be the Warrant Holder’s determination of whether this Warrant is exercisable (in
relation to other securities owned by such Warrant Holder) and of which portion of this Warrant is
exercisable, in each case subject to such aggregate percentage limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For
purposes of this Section 12, in determining the number of outstanding Shares, the Warrant Holder
may rely on the number of outstanding Shares as reflected in (x) the Company’s most recent Form
10-Q or Form 10-K, as the case may be, (y) a more recent public announcement by the Company or (z)
any other notice by the Company or the Company’s transfer agent setting forth the number of Shares
outstanding. Upon the written request of the Warrant Holder, the Company shall within three
Business Days confirm orally and in writing to such Warrant Holder the number of Shares. This
provision shall not restrict the number of Shares which a Warrant Holder may receive or
beneficially own in order to determine the amount of securities or other consideration that such
Warrant Holder may receive in the event of a transaction contemplated in Section 5 of this Warrant.
By written notice to the Company, which will not be effective until the 61st day after such notice
is delivered to the Company, the Warrant Holder may waive the provisions of this Section 12 (but
such waiver will not affect any other holder) to change the beneficial ownership limitation to
9.99% of the number of Shares outstanding immediately after giving effect to the issuance of Shares
upon exercise of this Warrant, and the provisions of this Section 12 shall continue to apply. Upon
such a change by a Warrant Holder of the beneficial ownership limitation from such 4.99% limitation
to such 9.99% limitation, the beneficial ownership limitation may not be further waived by such
Warrant Holder.

12.

 

     Section 13. Waivers; Amendments. Any provision of this Warrant may be amended or
waived with (but only with) the written consent of the Company and the Warrant Holder. No failure
or delay of the Company or the Warrant Holder in exercising any power or right hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such right or power,
or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other
or further exercise thereon or the exercise of any other right or power. No notice or demand on
the Company in any case shall entitle the Company to any other or future notice or demand in
similar or other circumstances. The rights and remedies of the Company and the Warrant Holder
hereunder are cumulative and not exclusive of any rights or remedies which it would otherwise have.

     Section 14. Miscellaneous.

     (a) Shareholder Rights. The Warrant shall not entitle any Warrant Holder, prior to
the exercise of the Warrant, to any voting rights as a shareholder of the Company.

     (b) Expenses. The Company shall pay all reasonable expenses of the Warrant Holder,
including reasonable fees and disbursements of counsel, in connection with the preparation of the
Warrant, any waiver or consent hereunder or any amendment or modification hereof (regardless of
whether the same becomes effective), or the enforcement of the provisions hereof; provided
that the Company shall not be required to pay any expenses of the Warrant Holder arising solely in
connection with a transfer of the Warrant.

     (c) Successors and Assigns. All the provisions of this Warrant by or for the benefit
of the Company or the Warrant Holder shall bind and inure to the benefit of their respective
successors and assigns.

     (d) Severability. In case any one or more of the provisions contained in this Warrant
shall be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein shall not in any way be affected or
impaired thereby. The parties shall endeavor in good faith negotiations to replace the invalid,
illegal or unenforceable provisions with valid provisions the economic effect of which comes as
close as possible to that of the invalid, illegal or unenforceable provisions.

     (e) Notices. Any notice or other communication hereunder shall be in writing and
shall be sufficient if sent by first-class mail or courier, postage prepaid, and addressed as
follows: (a) if to the Company, addressed to the Company at its address for notices as set forth
below its signature hereon or any other address as the Company may hereafter notify to the Warrant
Holder and(b) if to the Warrant Holder, addressed to such address as the Warrant Holder may
hereafter from time to time notify to the Company for the purposes of notice hereunder.

     (f) Equitable Remedies. Without limiting the rights of the Company and the Warrant
Holder to pursue all other legal and equitable rights available to such party for the other
parties’ failure to perform its obligations hereunder, the Company and the Warrant Holder each
hereto acknowledge and agree that the remedy at law for any failure to perform any obligations
hereunder would be inadequate and that each shall be entitled to specific performance, injunctive
relief or other equitable remedies in the event of any such failure.

     (g) Continued Effect. Rights and benefits conferred on the holders of Warrant Shares
pursuant to the provisions hereof (including Section 6) shall continue to inure to the
benefit of, and shall be enforceable by, such holders, notwithstanding the surrender of the Warrant
to, and its cancellation by, the Company upon the full or partial exercise or repurchase hereof.

13.

 

     (h) Confidentiality. The Warrant Holder agrees to keep confidential any proprietary
information relating to the Company delivered by the Company hereunder; provided that
nothing herein shall prevent the Warrant Holder from disclosing such information: (i) to any
holder of Warrants or Warrant Shares, (ii) to any Affiliate of any holder of Warrants or Warrant
Shares or any actual or potential transferee of the rights or obligations hereunder that agrees to
be bound by this Section 14(h), (iii) upon order, subpoena, or other process of any court
or administrative agency or otherwise required by law, (iv) upon the request or demand of any
regulatory agency or authority having jurisdiction over such party, (v) which has been publicly
disclosed, (vi) which has been obtained from any Person that is not a party hereto or an affiliate
of any such party, (vii) in connection with the exercise of any remedy, or the resolution of any
dispute hereunder, (viii) to the legal counsel or certified public accountants for any holder of
Warrants or Warrant Shares, or (ix) as otherwise expressly contemplated by this Warrant.

     (i) Governing Law. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH
THE INTERNAL LAWS OF THE STATE OF NEW YORK, EXCEPT AS OTHERWISE REQUIRED BY MANDATORY PROVISIONS OF
LAW.

     (j) Section Headings. The section headings used herein are for convenience of
reference only and shall not be construed in any way to affect the interpretation of any provisions
of the Warrant.

14.

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
signatory as of the day and year first above written.

	 	 	 	 	 
	 	Alexza Pharmaceuticals, Inc., a Delaware

corporation

 	 
	 	By  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 

Address for Notices: 2091 Stierlin Court

               
                  Mountain View, CA 94043

Facsimile: (650) 944-7999

1

 

Exhibit A to Warrant

Form of Notice of Exercise

                    ,20____

To: Alexza Pharmaceuticals, Inc.

     Reference is made to the Warrant dated October 5, 2009. Terms defined therein are used herein
as therein defined.

     The undersigned, pursuant to the provisions set forth in the Warrant, hereby irrevocably
elects and agrees to purchase                      Shares, and makes payment herewith in full therefor at the
Exercise Price of $                     in the following form: 

                                                            .

     [If the number of Shares as to which the Warrant is being exercised is less than all of the
Shares purchasable thereunder, the undersigned hereby requests that a new Warrant representing the
remaining balance of the Shares be registered in the name of                     , whose address is: 

                                        .]

     The undersigned hereby represents that it is exercising the Warrant for its own account or the
account of an Affiliate and not with the view to any sale or distribution and that the Warrant
Holder will not offer, sell or otherwise dispose of the Warrant or any underlying Warrant Shares in
violation of applicable securities laws.

	 	 	 	 	 
	 	[NAME OF WARRANT HOLDER]

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  

[ADDRESS OF WARRANT HOLDER]	 
	 

 

 

Exhibit B to Warrant

Form of Warrant Assignment

     Reference is made to the Warrant dated October 5, 2009, issued by Alexza Pharmaceuticals, Inc.
Terms defined therein are used herein as therein defined.

     FOR VALUE RECEIVED                      (the “Assignor”) hereby sells, assigns and transfers
all of the rights of the Assignor as set forth in such Warrant, with respect to the number of
Warrant Shares covered thereby as set forth below, to the Assignee(s) as set forth below:

     Number of Warrant Shares

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Number of Warrant	 
	Name(s) of Assignee(s)	 	Address(es)	 	 	Shares	 
	 
	 	 	 	 	 	 	 	 

     All notices to be given by the Company to the Assignor as Warrant Holder shall be sent to the
Assignee(s) at the above listed address(es), and, if the number of Shares being hereby assigned is
less than all of the Shares covered by the Warrant held by the Assignor, then also to the Assignor.

     In accordance with Section 7 of the Warrant, the Assignor requests that the Company execute
and deliver a new Warrant or Warrants in the name or names of the assignee or assignees, as is
appropriate, or, if the number of Shares being hereby assigned is less than all of the Shares
covered by the Warrant held by the Assignor, new Warrants in the name or names of the assignee or
the assignees, as is appropriate, and in the name of the Assignor.

     The undersigned represents that the Assignee has represented to the Assignor that the Assignee
is acquiring the Warrant for its own account or the account of an Affiliate for investment purposes
and not with the view to any sale or distribution, and that the Assignee will not offer, sell or
otherwise dispose of the Warrant or the Warrant Shares except under circumstances as will not
result in a violation of applicable securities laws.

     Dated:                     , 20___

	 	 	 	 	 
	 	[NAME OF ASSIGNOR]

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 

[ADDRESS OF ASSIGNOR]

 

 

APPENDIX A

Black Scholes Option Pricing formula to be used when calculating the value of each new warrant to
purchase one share in the Acquirer shall be:

CAcq = value of each warrant to purchase one share in the Acquirer

SAcq = price of Acquirer’s stock as determined by reference to the average of the
closing prices on the securities exchange or Nasdaq Global Market over the 20-day period ending
three trading days prior to the closing of the Corporate Reorganization described in Section 5(c)
if the Acquirer’s stock is then traded on such exchange or system, or the average of the closing
bid or sale prices (whichever is applicable) in the over-the-counter market over the 20-day period
ending three trading days prior to the closing of the Corporate Reorganization if the Acquirer’s
stock is then actively traded in the over-the-counter market, or the then most recently completed
financing if the Acquirer’s stock is not then traded on a securities exchange or system or in the
over-the-counter market.

TAcq = expiration date of new warrants to purchase shares in the Acquirer =
TCorp

tAcq = date of issue of new warrants to purchase shares in the Acquirer

TAcq-tAcq = time until warrant expiration, expressed in years

s  = volatility = annualized standard deviation of daily log-returns (using a 262-day annualization
factor) of the Acquirer’s stock price on the securities exchange or Nasdaq Global Market over a
20-day trading period, determined by the Warrant Holders, that is within the 100-day trading period
ending on the trading day immediately after the public announcement of the Corporate Reorganization
described in Section 5(c) if the Acquirer’s stock is then traded on such exchange or system, or the
annualized standard deviation of daily-log returns (using a 262-day annualization factor) of the
closing bid or sale prices (whichever is applicable) in the over-the-counter market over a 20-day
trading period, determined by the Warrant Holder, that is within the 100-day trading period ending
on the trading day immediately after the public announcement of the Corporate Reorganization if the
Acquirer’s stock is then actively traded in the over-the-counter market, or 0.6 (or 60%) if the
Acquirer’s stock is not then traded on a securities exchange or system or in the over-the-counter
market.

N = cumulative normal distribution function

ln = natural logarithm

λ = dividend rate of the Acquirer for the most recent 12-month period at the time of closing of the
Corporate Reorganization.

KAcq = strike price of new warrants to purchase shares in the Acquirer = KCorp
* (SAcq / SCorp)

r = annual yield, as reported by Bloomberg at time tAcq, of the United States Treasury
security measuring the nearest time TAcq

 

 

APPENDIX B

Black Scholes Option Pricing formula to be used when calculating the value of each Warrant to
purchase one share in the Company shall be:

CCorp = value of each Warrant to purchase one share in the Company

SCorp = price of Company stock as determined by reference to the average of the closing
prices on the securities exchange or Nasdaq Global Market over the 20-day period ending three
trading days prior to the closing of the Corporate Reorganization described in Section 5(c) if the
Company’s stock is then traded on such exchange or system, or the average of the closing bid or
sale prices (whichever is applicable) in the over-the-counter market over the 20-day period ending
three trading days prior to the closing of the Corporate Reorganization if the Company’s stock is
then actively traded in the over-the-counter market, or the then most recently completed financing
if the Company’s stock is not then traded on a securities exchange or system or in the
over-the-counter market.

TCorp = expiration date of Warrants to purchase shares in the Company

tCorp = date of public announcement of transaction

TCorp-tCorp = time until Warrant expiration, expressed in years

s  = volatility = the annualized standard deviation of daily log-returns (using a 262-day
annualization factor) of the Company’s stock price on the securities exchange or Nasdaq Global
Market over a 20-day trading period, determined by the Warrant Holders, that is within the 100-day
trading period ending on the trading day immediately after the public announcement of the Corporate
Reorganization described in Section 5(c) if the Company’s stock is then traded on such exchange or
system, or the annualized standard deviation of daily-log returns (using a 262-day annualization
factor) of the closing bid or sale prices (whichever is applicable) in the over-the-counter market
over a 20-day trading period, determined by the Warrant Holder, that is within the 100-day trading
period ending on the trading day immediately after the public announcement of the Corporate
Reorganization if the Company’s stock is then actively traded in the over-the-counter market, or
0.6 (or 60%) if the Company’s stock is not then traded on a securities exchange or system or in the
over-the-counter market.

N = cumulative normal distribution function

ln = natural logarithm

λ = dividend rate of the Company for the most recent 12-month period at the time of closing of the
Corporate Reorganization.

KCorp = strike price of warrant

r = annual yield, as reported by Bloomberg at time tCorp, of the United States Treasury
security measuring the nearest time TCorp

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]